# EDGAR Filing Document

**Accession Number:** 0001964738
**File Stem:** 0001964738-25-000091
**Filing Date:** 2025-11
**Character Count:** 169777
**Document Hash:** 7dc636273bcf6b10049be455cc3a6bb6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001964738-25-000091.hdr.sgml**: 20251106

**ACCESSION NUMBER**: 0001964738-25-000091

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 89

**CONFORMED PERIOD OF REPORT**: 20250930

**FILED AS OF DATE**: 20251106

**DATE AS OF CHANGE**: 20251106

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Solventum Corp
- **CENTRAL INDEX KEY:** 0001964738
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 922008841
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41968
- **FILM NUMBER:** 251459542

**BUSINESS ADDRESS:**
- **STREET 1:** C/O 3M COMPANY
- **STREET 2:** 3M CENTER, BUILDING 275-6W-02
- **CITY:** ST. PAUL
- **STATE:** MN
- **ZIP:** 55144-1000
- **BUSINESS PHONE:** 651-733-1110

**MAIL ADDRESS:**
- **STREET 1:** C/O 3M COMPANY
- **STREET 2:** 3M CENTER, BUILDING 275-6W-02
- **CITY:** ST. PAUL
- **STATE:** MN
- **ZIP:** 55144-1000

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** 3M Health Care Co
- **DATE OF NAME CHANGE:** 20230203

?xml version='1.0' encoding='ASCII'? solv-20250930

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 10-Q**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**For the quarterly period ended September 30, 2025** 

**or**

□**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from __________ to __________** 

**Commission file number: 001-41968**

**SOLVENTUM CORPORATION**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **92-2008841** |
| (State or other jurisdiction of incorporation) | (IRS Employer Identification No.) |
| **3M Center, Building 275-6W 2510 Conway Avenue East, Maplewood, Minnesota** | **55144** |
| (Address of Principal Executive Offices) | (Zip Code) |
| **(Registrant's Telephone Number, Including Area Code)** (651) 733-1110 | **(Registrant's Telephone Number, Including Area Code)** (651) 733-1110 |
| **Not Applicable** | **Not Applicable** |
| (Former Name or Former Address, if Changed Since Last Report) | (Former Name or Former Address, if Changed Since Last Report) |

---

---

| | | |
|:---|:---|:---|
| Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: |
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, Par Value $.01 Per Share | SOLV | New York Stock Exchange |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer,"" "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act:

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☐ |
| | | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

---

| | |
|:---|:---|
| **Class** | **Outstanding at October 31, 2025** |
| Common Stock, $0.01 par value per share | 173447557 |

---

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

**SOLVENTUM CORPORATION**

**Form 10-Q for the period ended September 30, 2025**

---

| | |
|:---|:---|
| **<u>**TABLE OF CONTENTS**</u>** | **<u>PAGE</u>** |
| <u>[PART I. Financial Information](#ib8564beecc4a4d00a2b8d983c25095ca)</u> | <u>[3](#ib8564beecc4a4d00a2b8d983c25095ca)</u> |
| &nbsp;&nbsp;&nbsp;<u>[Item 1. Financial Statements](#ia3228965f9b44aefb612aa5443829a56)</u> | <u>[3](#ia3228965f9b44aefb612aa5443829a56)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Income (Unaudited)](#i079427f05e044750ae53638762c3ae56)</u> | <u>[3](#i079427f05e044750ae53638762c3ae56)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)](#idb4b3533220f434697a14301606a861e)</u> | <u>[4](#idb4b3533220f434697a14301606a861e)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Balance Sheets (Unaudited)](#i2abd9e7d23364fdb83c5bfdb04b73ca3)</u> | <u>[5](#i2abd9e7d23364fdb83c5bfdb04b73ca3)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Changes in Equity (Unaudited)](#i6ee029a77cfa4437935f24275565a92f)</u> | <u>[6](#i6ee029a77cfa4437935f24275565a92f)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statements of Cash Flows (Unaudited)](#i0fca0bdffd834b138cb6f62f3bd6a356)</u> | <u>[7](#i0fca0bdffd834b138cb6f62f3bd6a356)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Notes to the Condensed Consolidated Financial Statements (Unaudited)](#i6e5a86596ba148b08e66b1f53998651a)</u> | <u>[8](#i6e5a86596ba148b08e66b1f53998651a)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[NOTE 1. Significant Accounting Policies](#ia650f3c0b6614e65b5ddf470a0dfee72)</u> | <u>[8](#ia650f3c0b6614e65b5ddf470a0dfee72)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[NOTE 2. Revenue Recognition](#i6552b6a05e6244028bef16d155498407)</u> | <u>[9](#i6552b6a05e6244028bef16d155498407)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[NOTE 3. Acquisitions and Divestitures](#i7c6201084b034d3f996ea4a9f4d097a2)</u> | <u>[9](#i7c6201084b034d3f996ea4a9f4d097a2)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[NOTE 4. Goodwill and Intangible Assets](#i3aa2b745b2dd47aeb94ae890c2a9444b)</u> | <u>[10](#i3aa2b745b2dd47aeb94ae890c2a9444b)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[NOTE 5. Other Current Liabilities](#id228efd4d5f845baaa3a7294aa9f0cd5)</u> | <u>[11](#id228efd4d5f845baaa3a7294aa9f0cd5)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[NOTE 6. Property, Plant, and Equipment - Net](#ie56b2e86271641f88a43c0753a4fca36)</u> | <u>[11](#ie56b2e86271641f88a43c0753a4fca36)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[NOTE 7. Comprehensive Income Information](#i84c41708f5af41a2bdc04f4990706305)</u> | <u>[12](#i84c41708f5af41a2bdc04f4990706305)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[NOTE 8. Income Taxes](#if4073c56dcff471583f84a57c6f76e27)</u> | <u>[13](#if4073c56dcff471583f84a57c6f76e27)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[NOTE 9. Long-Term Debt and Short-Term Borrowings](#i1a420d344b3d424eabe148f7742730e2)</u> | <u>[14](#i1a420d344b3d424eabe148f7742730e2)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[NOTE 10. Pension and Postretirement Benefit Plans](#i8b2590185c634baab1e5ed70d0af1f8d)</u> | <u>[15](#i8b2590185c634baab1e5ed70d0af1f8d)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[NOTE 11. Derivatives](#i9135b06792604991b59578474ea31219)</u> | <u>[17](#i9135b06792604991b59578474ea31219)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[NOTE 12. Commitments and Contingencies](#i0ccbf737f75148e9800a90b1e4bc6219)</u> | <u>[19](#i0ccbf737f75148e9800a90b1e4bc6219)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[NOTE 13. Restructuring](#i7c0f0175efd7436d98a35e756248a0d8)</u> | <u>[21](#i7c0f0175efd7436d98a35e756248a0d8)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[NOTE 14. Earnings Per Share](#ia964c2efa2894b03a320a45fbbb9bfee)</u> | <u>[22](#ia964c2efa2894b03a320a45fbbb9bfee)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[NOTE 15. Stock-Based Compensation](#i87350e0d6dd64fbc88883dc0498f5a88)</u> | <u>[22](#i87350e0d6dd64fbc88883dc0498f5a88)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[NOTE 16. Related Parties](#i3a1c5d19807c470ab32243093673da8b)</u> | <u>[23](#i3a1c5d19807c470ab32243093673da8b)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[NOTE 17. Business Segments](#i6fa35b02f89e4d6a98c4bfe3ff1f7d9a)</u> | <u>[24](#i6fa35b02f89e4d6a98c4bfe3ff1f7d9a)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[NOTE 18. Subsequent Events](#i84f31caa4e544166af35d0330c1a342d)</u> | <u>[26](#i84f31caa4e544166af35d0330c1a342d)</u> |
| &nbsp;&nbsp;&nbsp;<u>[Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](#i647db893acc5442eb23ec05d78aa4765)</u> | <u>[26](#i647db893acc5442eb23ec05d78aa4765)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Overview](#i5dd2c2de6fc2477f996ebe60316a8e06)</u> | <u>[26](#i5dd2c2de6fc2477f996ebe60316a8e06)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Results of Operations](#i1a27f90ae37c4d2d9f0a0e8f175e74e3)</u> | <u>[30](#i1a27f90ae37c4d2d9f0a0e8f175e74e3)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Performance by Business Segment](#ia4da62567ee446acb0b055bcd7e9e8bf)</u> | <u>[32](#ia4da62567ee446acb0b055bcd7e9e8bf)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Financial Condition and Liquidity](#i718f51cfd1fe4a8aa2f2f681fc89a500)</u> | <u>[35](#i718f51cfd1fe4a8aa2f2f681fc89a500)</u> |
| <u>[Cautionary Note Concerning Forward Looking Statements](#ia0ab31fdcdc646eb922d6bf3c592c4b7)</u> | <u>[37](#ia0ab31fdcdc646eb922d6bf3c592c4b7)</u> |
| &nbsp;&nbsp;&nbsp;<u>[Item 3. Quantitative and Qualitative Disclosures About Market Risk](#ifa5e9a98d7734743a1c6293bf499eb3b)</u> | <u>[38](#ifa5e9a98d7734743a1c6293bf499eb3b)</u> |
| &nbsp;&nbsp;&nbsp;<u>[Item 4. Controls and Procedures](#i8d18b5609a4443c893076001813059f5)</u> | <u>[38](#i8d18b5609a4443c893076001813059f5)</u> |
| <u>[PART II. Other Information](#ica611177fd634811aa55ea8315083608)</u> | <u>[39](#ica611177fd634811aa55ea8315083608)</u> |
| &nbsp;&nbsp;&nbsp;<u>[Item 1. Legal Proceedings](#i21bd34f525fe450bb693b2c32a019b99)</u> | <u>[39](#i21bd34f525fe450bb693b2c32a019b99)</u> |
| &nbsp;&nbsp;&nbsp;<u>[Item 1A. Risk Factors](#ie69ebf7000154076ba0c414eed490b2c)</u> | <u>[39](#ie69ebf7000154076ba0c414eed490b2c)</u> |
| &nbsp;&nbsp;&nbsp;<u>[Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](#i31ac30e3f5104868aacb3e4406941845)</u> | <u>[39](#i31ac30e3f5104868aacb3e4406941845)</u> |
| &nbsp;&nbsp;&nbsp;<u>[Item 3. Defaults Upon Senior Securities](#i426bae8ce58944fd971dba61530458b5)</u> | <u>[39](#i426bae8ce58944fd971dba61530458b5)</u> |
| &nbsp;&nbsp;&nbsp;<u>[Item 4. Mine Safety Disclosures](#i008a7dd6c8fa40f795acd6cc73d3a8d2)</u> | <u>[39](#i008a7dd6c8fa40f795acd6cc73d3a8d2)</u> |
| &nbsp;&nbsp;&nbsp;<u>[Item 5. Other Information](#idd6a719d6c254aea8075b0f887ea2658)</u> | <u>[39](#idd6a719d6c254aea8075b0f887ea2658)</u> |
| &nbsp;&nbsp;&nbsp;<u>[Item 6. Exhibits](#i3729c5edf3e643c59c24bb7cf239189a)</u> | <u>[40](#i3729c5edf3e643c59c24bb7cf239189a)</u> |

---

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

**SOLVENTUM CORPORATION**

**FORM 10-Q**

**For the Quarterly Period Ended September 30, 2025**

**PART I. Financial Information**

**Item 1. Financial Statements**

**Solventum Corporation**

**Condensed Consolidated Statements of Income (Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
|<br>**(Millions, except per share data)** | **2025** | **2024** | **2025** | **2024** |
| Net sales of product | $1594 | $1608 | $4859 | $4766 |
| Net sales of software and rentals | 502 | 474 | 1468 | 1413 |
| &nbsp;&nbsp;Total net sales | 2096 | 2082 | 6327 | 6179 |
| Cost of product | 847 | 793 | 2547 | 2341 |
| Cost of software and rentals | 114 | 124 | 356 | 364 |
| &nbsp;&nbsp;Gross profit | 1135 | 1165 | 3424 | 3474 |
| Selling, general and administrative expenses | 780 | 701 | 2321 | 1998 |
| Research and development expenses | 183 | 189 | 564 | 576 |
| Gain on sale of business | (1518) |  | (1518) |  |
| Operating income | 1690 | 275 | 2057 | 900 |
| Interest expense, net | 89 | 107 | 296 | 260 |
| Loss on debt extinguishment, net | 82 |  | 82 |  |
| Other expense (income), net | 5 | 1 | 24 | 48 |
| Income before income taxes | 1514 | 167 | 1655 | 592 |
| Provision for (benefit from) income taxes | 248 | 45 | 162 | 144 |
| Net income | $1266 | $122 | $1493 | $448 |
| Earnings per share: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic earnings per share | $7.26 | $0.70 | $8.58 | $2.59 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted earnings per share | 7.22 | 0.70 | 8.53 | 2.58 |
| Weighted-average number of shares outstanding: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | 174.3 | 173.4 | 174.0 | 173.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | 175.4 | 173.9 | 175.1 | 173.4 |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

**Solventum Corporation**

**Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
|<br>**(Millions)** | **2025** | **2024** | **2025** | **2024** |
| Net income | $1266 | $122 | $1493 | $448 |
| Other comprehensive income (loss), net of tax: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cumulative translation adjustment | (24) | 179 | 414 | 94 |
| &nbsp;&nbsp;&nbsp;&nbsp;Defined benefit pension and postretirement plans | 44 | 10 | 70 | 20 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash flow hedging instruments | 7 | (11) | (32) | (10) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total other comprehensive income (loss), net of tax | 27 | 178 | 452 | 104 |
| Comprehensive income | $1293 | $300 | $1945 | $552 |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

**Solventum Corporation**

**Condensed Consolidated Balance Sheets (Unaudited)**

---

| | | |
|:---|:---|:---|
| | **September 30,** | **December 31,** |
|<br>**(Millions, except share information)** | **2025** | **2024** |
| **Assets** |  |  |
| Current assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $1642 | $762 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable — net of allowances of $86 and $86 | 1019 | 1044 |
| &nbsp;&nbsp;&nbsp;&nbsp;Due from related parties | 157 | 185 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Finished goods | 625 | 539 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Work in process | 191 | 190 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Raw materials and supplies | 233 | 236 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total inventories | 1049 | 965 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current assets | 540 | 293 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 4407 | 3249 |
| Property, plant and equipment — net | 1336 | 1622 |
| Goodwill | 5260 | 6377 |
| Intangible assets — net | 2223 | 2544 |
| Other assets | 747 | 665 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $13973 | $14457 |
| **Liabilities** |  |  |
| Current liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Short-term borrowings and current portion of long-term debt | $— | $200 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 669 | 618 |
| &nbsp;&nbsp;&nbsp;&nbsp;Due to related parties | 464 | 272 |
| &nbsp;&nbsp;&nbsp;&nbsp;Unearned revenue | 576 | 572 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current liabilities | 1229 | 1041 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 2938 | 2703 |
| Long-term debt | 5137 | 7810 |
| Pension and postretirement benefits | 306 | 350 |
| Deferred income taxes | 169 | 225 |
| Other liabilities | 437 | 410 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | $8987 | $11498 |
| Commitments and contingencies (Note 12) |  |  |
| **Equity** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock, par value $0.01 per share, 750,000,000 shares authorized | $2 | $2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares issued and outstanding - September 30, 2025: 173,439,525  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares issued and outstanding - December 31, 2024: 172,785,606 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in-capital | 3854 | 3771 |
| &nbsp;&nbsp;&nbsp;&nbsp;Retained earnings | 1734 | 242 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive income (loss)  | (604) | (1056) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total equity | 4986 | 2959 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and equity | $13973 | $14457 |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

**Solventum Corporation**

**Condensed Consolidated Statements of Changes in Equity (Unaudited)**

**Three Months Ended September 30, 2025 and September 30, 2024**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | | | | | |
|<br>**(Millions)** | **Shares Outstanding** | **Par Value** |<br>**Additional Paid-In-Capital** |<br>**Retained Earnings** |<br>**Net Parent Investment** |<br>**Accumulated Other Comprehensive Income (Loss)** |<br>**Total** |
| **Balance at June 30, 2025** | 173 | $2 | $3806 | $468 | $— | $(631) | $3645 |
| Net income |  |  |  | 1266 |  |  | 1266 |
| Other comprehensive income (loss), net of tax |  |  |  |  |  | 27 | 27 |
| Net transfers from 3M |  |  | 9 |  |  |  | 9 |
| Stock-based compensation |  |  | 41 |  |  |  | 41 |
| Common stock for tax withholding obligations |  |  | (2) |  |  |  | (2) |
| **Balance at September 30, 2025** | 173 | $2 | $3854 | $1734 | $— | $(604) | $4986 |
| **Balance at June 30, 2024** | 173 | $2 | $3719 | $89 | $— | $(943) | $2867 |
| Net income |  |  |  | 122 |  |  | 122 |
| Other comprehensive income (loss), net of tax |  |  |  |  |  | 178 | 178 |
| Stock-based compensation |  |  | 27 |  |  |  | 27 |
| Common stock for tax withholding obligations |  |  | (2) |  |  |  | (2) |
| **Balance at September 30, 2024** | 173 | $2 | $3744 | $211 | $— | $(765) | $3192 |

---

**Nine Months Ended September 30, 2025 and September 30, 2024**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | | | | | |
| **(Millions)** | **Shares Outstanding** | **Par Value** |<br>**Additional Paid-In-Capital** |<br>**Retained Earnings** |<br>**Net Parent Investment** |<br>**Accumulated Other Comprehensive Income (Loss)** |<br>**Total** |
| **Balance at December 31, 2024** | 173 | $2 | $3771 | $242 | $— | $(1056) | $2959 |
| Net income |  |  |  | 1493 |  |  | 1493 |
| Other comprehensive income (loss), net of tax |  |  |  |  |  | 452 | 452 |
| Net transfers to 3M |  |  | (21) |  |  |  | (21) |
| Stock-based compensation |  |  | 124 |  |  |  | 124 |
| Common stock for tax withholding obligations |  |  | (20) |  |  |  | (20) |
| **Balance at September 30, 2025** | 173 | $2 | $3854 | $1734 | $— | $(604) | $4986 |
| **Balance at December 31, 2023** |  | $— | $— | $— | $12003 | $(337) | $11666 |
| Net income |  |  |  | 211 | 237 |  | 448 |
| Other comprehensive income (loss), net of tax |  |  |  |  |  | 104 | 104 |
| Net transfers to 3M |  |  |  |  | (8575) | (532) | (9107) |
| Stock-based compensation |  |  | 83 |  |  |  | 83 |
| Common stock for tax withholding obligations |  |  | (2) |  |  |  | (2) |
| Issuance of common stock in connection with Spin-Off and reclassification of net parent investment | 173 | 2 | 3663 |  | (3665) |  |  |
| **Balance at September 30, 2024** | 173 | $2 | $3744 | $211 | $— | $(765) | $3192 |

---

The accompanying Notes to the Consolidated Financial Statements are an integral part of these statements.

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

**Solventum Corporation**

**Condensed Consolidated Statements of Cash Flows (Unaudited)**

---

| | | |
|:---|:---|:---|
| | **Nine months ended September 30,** | **Nine months ended September 30,** |
|<br>**(Millions)** | **2025** | **2024** |
| **Cash Flows from Operating Activities** |  |  |
| Net income | $1493 | $448 |
| Adjustments to reconcile net income to net cash provided by operating activities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 372 | 405 |
| &nbsp;&nbsp;&nbsp;&nbsp;Pension and postretirement benefit expense | 49 | 30 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense | 124 | 87 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on sale of business | (1518) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Purification and Filtration transaction costs | (86) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | (47) | (93) |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in assets and liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | 36 | 14 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Due from related parties | 37 | 200 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | (134) | (99) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 74 | 200 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Due to related parties | 18 | (321) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued compensation | (9) | 53 |
| &nbsp;&nbsp;&nbsp;&nbsp;All other operating activities — net | (135) | 42 |
| Net cash provided by operating activities | 274 | 966 |
| **Cash Flows from Investing Activities** |  |  |
| Purchases of property, plant and equipment | (316) | (253) |
| Proceeds from sale of business | 3870 |  |
| Other — net | (12) |  |
| Net cash provided by (used in) investing activities | 3542 | (253) |
| **Cash Flows from Financing Activities** |  |  |
| Repayment of debt | (2970) | (200) |
| Net transfers to 3M | (21) | (8247) |
| Proceeds from long-term debt, net of issuance costs |  | 8303 |
| Other — net | 49 | 8 |
| Net cash used in financing activities | (2942) | (136) |
| Effect of exchange rate changes on cash and cash equivalents | 6 | 1 |
| Net increase (decrease) in cash and cash equivalents | 880 | 578 |
| Cash and cash equivalents at beginning of period | 762 | 194 |
| Cash and cash equivalents at end of period | $1642 | $772 |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

**Solventum Corporation**

**Notes to the Condensed Consolidated Financial Statements (Unaudited)**

**NOTE 1. Significant Accounting Policies**

***Organization and Description of Business***

Solventum Corporation ("Solventum" or the "Company") was a business of 3M Company ("3M"). On April 1, 2024 (the "Distribution Date"), 3M completed the previously announced spin-off of Solventum Corporation (the "Spin-Off"). The Spin-Off was completed through a distribution of approximately 80.1% of the Company's outstanding common stock to holders of record of 3M's common stock as of the close of business on March 18, 2024 (the "Distribution"), which resulted in the issuance of 172,709,505 shares of common stock. As a result of the Distribution, the Company became an independent public company. Solventum's common stock is listed under the symbol "SOLV" on the New York Stock Exchange ("NYSE").

Solventum is a leading global healthcare company with a broad portfolio of trusted solutions that leverage deep material science, data science, and digital capabilities to address critical customer needs. Solventum is organized into three reportable business segments that are aligned with the end markets that the Company serves: MedSurg, Dental Solutions and Health Information Systems.

***Basis of Presentation***

The unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission ("SEC") and present the financial position, results of operations, and cash flows for the periods presented. The interim condensed consolidated financial statements are unaudited but, in the opinion of management, reflect all adjustments necessary for a fair statement of the Company's consolidated financial position, results of operations and cash flows for the periods presented. These adjustments consist of normal, recurring items. The results of operations for any interim periods are not necessarily indicative of results for the full year.

The Company's financial statements are presented on a consolidated basis. Prior to April 1, 2024, Solventum was a carve-out business of 3M. The Company's financial statements prior to April 1, 2024 were prepared on a combined basis and were derived from the consolidated financial statements and accounting records of 3M, including the historical cost basis of assets and liabilities comprising the Company, as well as the historical revenues, direct costs, and allocations of indirect costs attributable to the operations of the Company, using the historical accounting policies applied by 3M. The financial statements included in this interim report are referred to as the "Condensed Consolidated Financial Statements" for all periods presented.

All amounts discussed are in millions of U.S. dollars, unless otherwise indicated. Amounts reported within this interim report are rounded to the nearest million and the sum of the components may not equal the total amount reported due to rounding. Additionally, certain columns and rows within tables may not sum due to rounding.

All intercompany transactions and balances within Solventum have been eliminated. These unaudited condensed consolidated financial statements include certain transactions with 3M, which are disclosed as related party transactions in Note 16, "Related Parties".

The unaudited condensed consolidated financial statements and related notes should be read in conjunction with the audited consolidated financial statements and related notes included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the "2024 Annual Report").

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

**New Accounting Pronouncements**

The table below provides summaries of recently issued financial accounting standards.

---

| | | | |
|:---|:---|:---|:---|
| ***Standard*** | **Relevant Description** | **Effective Date for Solventum** | **Impact of Adoption** |
| ASU No. 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures* | Issued in December 2023. Requires disaggregated information about a Company's effective tax rate reconciliation as well as information on income taxes paid. | Year-end December 31, 2025 | The Company is currently assessing the impact that the updated standard will have on financial statement disclosures. |
| ASU No. 2024-03, *Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses* | Issued in November 2024. Requires additional disclosure of the nature of expenses included in the income statement. | Year-end December 31, 2027 | The Company is currently assessing the impact that the updated standard will have on financial statement disclosures. |
| ASU No. 2025-06, *Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software* | Issued September 2025. Updates existing accounting guidance regarding the capitalization of internal-use software costs. | January 1, 2028 | The Company is currently assessing the impact that the updated standard will have on financial statement disclosures. |

---

**NOTE 2. Revenue Recognition**

***Contract Balances***

Unearned revenue primarily relates to revenue that is recognized over time for one-year software license contracts. Approximately $98 million and $477 million of the December 31, 2024 balance was recognized as revenue during the three and nine months ended September 30, 2025, while approximately $110 million and $500 million of the December 31, 2023 balance was recognized as revenue during the three and nine months ended September 30, 2024.

***Operating Lease Revenue***

Sales of software and rental includes rental revenue from durable medical devices as part of operating lease arrangements (reported within the MedSurg segment), which was $157 million and $456 million for the three and nine months ended September 30, 2025, and $148 million and $442 million for the three and nine months ended September 30, 2024.

***Customer Concentration***

No customer accounted for more than 10% of the Company's revenues for the three and nine months ended September 30, 2025 or 2024. Additionally, no customers accounted for more than 10% of accounts receivable as of September 30, 2025 or December 31, 2024.

**NOTE 3. Acquisitions and Divestitures**

***Acquisitions***

The Company had no acquisitions during the three and nine months ended September 30, 2025 or 2024.

***Divestitures***

On February 25, 2025, the Company entered into a Transaction Agreement to sell its Purification and Filtration business to Thermo Fisher Scientific Inc. ("Buyer"). On June 25, 2025, the Company and Buyer entered into an Amended and Restated Transaction Agreement (the "Agreement") to exclude the Company's drinking water filtration business (the "Water Business") from the scope of the Purification and Filtration business to be acquired by Buyer (such acquired business, the "Business").

On September 1, 2025, Solventum completed the sale of the Business to the Buyer. The cash consideration paid to Solventum at closing was approximately $4 billion, which is subject to further working capital adjustments, resulting in a pre-tax gain of approximately $1.5 billion. The pre-tax gain was recorded net of transaction fees of $86 million.

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

Under the Agreement, Buyer is entitled to receive a payment of up to $75 million from the Company either upon a sale of the Water Business or after an agreed upon 3-year period. The Company recorded $64 million within the other liabilities on the condensed consolidated balance sheets, which was the present value of the expected future obligation at close of the Transaction.

In connection with the sale of the Business, the Company entered into various transition service agreements to provide certain support services at cost, below fair market value, for a period of up to 24 months from the closing of the sale. These transition services include product distribution and supply chain management, contract manufacturing, information technology, finance, customer support, among others. In connection with these agreements, the Company recognized an unfavorable contract liability of $113 million, which will be recognized over the terms of the agreements.

In September 2025, the Company recognized approximately $14 million of transition service income, including amortization of the unfavorable contract liability, within selling, general and administrative expenses on the Company's condensed consolidated statements of income. Sales and cost of sales associated with products sold to Buyer, as well as cost of products purchased from Buyer under the supply agreements were not material.

Immediately following the closing, the Company repurchased inventory from Buyer to fulfill its product distribution services under the transition agreement with Buyer. The Company recorded $83 million within other current liabilities on the condensed consolidated balance sheets related to this repurchase that the Company expects to pay in the fourth quarter of 2025.

**NOTE 4. Goodwill and Intangible Assets**

***Goodwill***

There was no goodwill recorded from acquisitions during the nine months ended September 30, 2025.

The goodwill balance by business segment is as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **(Millions)** | **MedSurg** | **Dental Solutions** | **Health Information Systems** | **Purification and Filtration** | **All Other** | **Total** |
| Balance as of December 31, 2024 | $3597 | $439 | $871 | $1470 | $— | $6377 |
| &nbsp;&nbsp;Translation and other | 203 | 37 | 4 | (80) | 108 | 272 |
| &nbsp;&nbsp;Divestiture activity |  |  |  | (1389) |  | (1389) |
| Balance as of September 30, 2025 | $3800 | $477 | $875 | $— | $108 | $5260 |

---

***Acquired Intangible Assets:*** The carrying amount and accumulated amortization of acquired finite-lived intangible assets are as follows:

---

| | | |
|:---|:---|:---|
|<br>**(Millions)** | **September 30,**<br>**2025** | **December 31,**<br>**2024** |
| Customer related intangible assets | $2070 | $2720 |
| Patents and other technology-based intangible assets | 1632 | 1895 |
| Tradenames and other amortizable intangible assets | 611 | 729 |
| &nbsp;&nbsp;Total gross carrying amount | 4313 | 5344 |
| Accumulated amortization — customer related | (741) | (1208) |
| Accumulated amortization — patents and other technology-based | (1068) | (1224) |
| Accumulated amortization — tradenames and other | (281) | (368) |
| &nbsp;&nbsp;Total accumulated amortization | (2090) | (2800) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total intangible assets — net | $2223 | $2544 |

---

Amortization expense was as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
|<br>**(Millions)** | **2025** | **2024** | **2025** | **2024** |
| Amortization expense | $77 | $88 | $235 | $261 |

---

Expected amortization expense for acquired amortizable intangible assets recorded as of September 30, 2025 is as follows:

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **(Millions)** | **Remainder of 2025** | **2026** | **2027** | **2028** | **2029** | **2030** | **After 2030** |
| Amortization expense | $77 | $305 | $300 | $296 | $257 | $152 | $836 |

---

**NOTE 5. Other Current Liabilities**

Other current liabilities included in the condensed consolidated balance sheets consist of the following:

---

| | | |
|:---|:---|:---|
|<br>**(Millions)** | **September 30,**<br>**2025** | **December 31,**<br>**2024** |
| **Other current liabilities** |  |  |
| Accrued compensation | $259 | $281 |
| Accrued taxes | 212 | 122 |
| Accrued rebates | 171 | 146 |
| Accrued interest | 41 | 114 |
| Purification and Filtration-related | 193 |  |
| Other | 353 | 378 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total other current liabilities | $1229 | $1041 |

---

Purification and Filtration-related in the table above includes the liability recorded in conjunction with the repurchase of inventory and the current portion of the unfavorable contract liability as described in Note 3, along with other activity with Buyer, including amounts owed under the transition agreements, since the close of the Transaction.

**NOTE 6. Property, Plant, and Equipment - Net** 

Property, plant and equipment - net consisted of the following:

---

| | | |
|:---|:---|:---|
|<br>**(Millions)** | **September 30,**<br>**2025** | **December 31,**<br>**2024** |
| **Property, plant and equipment - at cost** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Buildings and leasehold improvements | $832 | $956 |
| &nbsp;&nbsp;&nbsp;&nbsp;Machinery and equipment | 1779 | 2150 |
| &nbsp;&nbsp;&nbsp;&nbsp;Construction in progress | 568 | 504 |
| Gross property, plant and equipment | 3179 | 3610 |
| Accumulated depreciation | (1843) | (1988) |
| Property, plant and equipment - net | $1336 | $1622 |

---

Depreciation expense consisted of the following:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
|<br>**(Millions)** | **2025** | **2024** | **2025** | **2024** |
| Depreciation expense | $37 | $37 | $117 | $121 |

---

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

**NOTE 7. Comprehensive Income Information** 

***Changes in Accumulated Other Comprehensive Income (Loss) by Component***

The table below presents the changes in accumulated other comprehensive income (loss) ("AOCI"), including the reclassifications out of AOCI by component:

**Three months ended September 30, 2025**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **(Millions)** | **Cumulative Translation Adjustment** | **Defined Benefit Pension and Postretirement Plans** | **Cash Flow Hedging** | **Total Accumulated Other Comprehensive Income (Loss)** |
| **Balance at June 30, 2025, net of tax:** | $(112) | $(500) | $(19) | $(631) |
| Other comprehensive income (loss), before tax: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Amount of gain (loss) recognized in AOCI | (23) | 55 | 6 | 38 |
| &nbsp;&nbsp;&nbsp;Amount of gain (loss) reclassified from AOCI |  | 6 | 3 | 9 |
| Total other comprehensive income (loss), before tax | (23) | 61 | 9 | 47 |
| Tax effect | (1) | (17) | (2) | (20) |
| Total other comprehensive income (loss), net of tax | (24) | 44 | 7 | 27 |
| **Balance at September 30, 2025, net of tax:** | $(136) | $(456) | $(12) | $(604) |

---

**Three months ended September 30, 2024**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **(Millions)** | **Cumulative Translation Adjustment** | **Defined Benefit Pension and Postretirement Plans** | **Cash Flow Hedging** | **Total Accumulated Other Comprehensive Income (Loss)** |
| **Balance at June 30, 2024, net of tax:** | $(432) | $(512) | $1 | $(943) |
| Other comprehensive income (loss), before tax: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Amount of gain (loss) recognized in AOCI | 179 |  | (15) | 164 |
| &nbsp;&nbsp;&nbsp;Amount of gain (loss) reclassified from AOCI |  | 13 |  | 13 |
| Total other comprehensive income (loss), before tax | 179 | 13 | (15) | 177 |
| Tax effect |  | (3) | 4 | 1 |
| Total other comprehensive income (loss), net of tax | 179 | 10 | (11) | 178 |
| **Balance at September 30, 2024, net of tax:** | $(253) | $(502) | $(10) | $(765) |

---

**Nine months ended September 30, 2025**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **(Millions)** | **Cumulative Translation Adjustment** | **Defined Benefit Pension and Postretirement Plans** | **Cash Flow Hedging** | **Total Accumulated Other Comprehensive Income (Loss)** |
| **Balance at December 31, 2024, net of tax:** | $(550) | $(526) | $20 | $(1056) |
| Other comprehensive income (loss), before tax: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Amount of gain (loss) recognized in AOCI | 395 | 55 | (37) | 413 |
| &nbsp;&nbsp;&nbsp;Amount of gain (loss) reclassified from AOCI |  | 41 | (4) | 37 |
| Total other comprehensive income (loss), before tax | 395 | 96 | (41) | 450 |
| Tax effect | 19 | (26) | 9 | 2 |
| Total other comprehensive income (loss), net of tax | 414 | 70 | (32) | 452 |
| **Balance at September 30, 2025, net of tax:** | $(136) | $(456) | $(12) | $(604) |

---

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

**Nine months ended September 30, 2024** 

---

| | | | | |
|:---|:---|:---|:---|:---|
| **(Millions)** | **Cumulative Translation Adjustment** | **Defined Benefit Pension and Postretirement Plans** | **Cash Flow Hedging** | **Total Accumulated Other Comprehensive Income (Loss)** |
| **Balance at December 31, 2023, net of tax:** | $(347) | $10 | $— | $(337) |
| Other comprehensive income (loss), before tax: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Amount of gain (loss) recognized in AOCI | 56 |  | (13) | 43 |
| &nbsp;&nbsp;&nbsp;Amount of gain (loss) reclassified from AOCI | 38 | 26 |  | 64 |
| Total other comprehensive income (loss), before tax | 94 | 26 | (13) | 107 |
| Tax effect |  | (6) | 3 | (3) |
| Total other comprehensive income (loss), net of tax | 94 | 20 | (10) | 104 |
| Transfers from 3M, net of tax |  | (532) |  | (532) |
| **Balance at September 30, 2024, net of tax:** | $(253) | $(502) | $(10) | $(765) |

---

Additional details on the amounts reclassified from AOCI into consolidated income include:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cumulative translation adjustment: amounts were reclassified into other expense (income), net and were related to charges associated with the substantial liquidation of foreign operations completed as part of our separation from 3M.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Defined benefit pension and postretirement plans: amounts were reclassified into other expense (income), net (see Note 10).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cash flow hedging: foreign currency forward contracts amounts were reclassified into cost of sales (see Note 11).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The tax effects, if applicable, associated with these reclassifications were reflected in provision for (benefit from) income taxes.

**NOTE 8. Income Taxes** 

The Company's income tax provision through March 31, 2024 was prepared on a separate return basis. The income tax provision post Spin-Off is prepared on a stand-alone basis.

The effective tax rates for the three months ended September 30, 2025 and 2024 were 16.4% and 26.9%, respectively. The decrease in our effective tax rate is primarily related to the divestiture of the Purification and Filtration business.

The effective tax rates for the nine months ended September 30, 2025 and 2024 were 9.8% and 24.3%, respectively. The decrease in our effective tax rate is primarily related to the divestiture of the Purification and Filtration business.

The Company's income tax provision or benefit for the interim periods is determined based on an estimated annual effective tax rate, adjusted for discrete items. Because significant foreign earnings are generated by the Company's subsidiaries organized in jurisdictions with lower statutory tax rates, the Company's estimated annual effective tax rate may be materially impacted if earnings in these lower-tax jurisdictions fluctuate.

The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized based on evaluation of all available positive and negative evidence. On the basis of this evaluation, the Company continues to maintain a valuation allowance to reduce its deferred tax assets to the amount realizable.

In 2021, the Organisation for Economic Co-operation and Development ("OECD") announced Pillar Two Model Rules which call for the taxation of large multinational corporations at a global minimum tax rate of 15%. Many non-U.S. tax jurisdictions, including Ireland, have either recently enacted legislation to adopt certain components of the Pillar Two Model Rules beginning in fiscal year 2024 or announced their plans to enact legislation in future years. In the nine months ended September 30, 2025, the Company incurred an insignificant tax impact in connection with Pillar Two.

On July 4, 2025, the One Big Beautiful Bill Act (the "Act") was enacted in the U.S. The Act includes changes to U.S. corporate income tax provisions, including immediate expensing of domestic Research and Development costs, 100% bonus depreciation, modified limits of interest deductibility, and revisions to U.S. international tax provisions. The Act did not materially impact the Company's income tax provision for the three and nine months ended September 30, 2025. The Company will continue to monitor and evaluate the potential tax impacts of the Act in future periods.

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

**NOTE 9. Long-Term Debt and Short-Term Borrowings**

Carrying value includes the impact of debt issuance costs. Long-term debt and short-term borrowings as of September 30, 2025 and December 31, 2024 consisted of the following:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **(Millions)** | **Currency/ Fixed vs. Floating** | **Effective Interest Rate** | **Final Maturity Date** | **Carrying Value** | **Carrying Value** |
| **Description** | **Currency/ Fixed vs. Floating** | **Effective Interest Rate** | **Final Maturity Date** | **September 30, 2025** | **December 31, 2024** |
| Eighteen month senior term loan credit facility | USD Floating | —% | 2025 | $— | $200 |
| Three year senior term loan credit facility | USD Floating | 5.53 | 2027 | 210 | 979 |
| $1 billion 5.45 percent three year senior notes | USD Fixed | 5.36 | 2027 | 349 | 995 |
| $1.5 billion 5.40 percent five year senior notes | USD Fixed | 5.23 | 2029 | 698 | 1487 |
| $1 billion 5.45 percent seven year senior notes | USD Fixed | 5.22 | 2031 | 991 | 990 |
| $1.65 billion 5.60 percent ten year senior notes | USD Fixed | 5.39 | 2034 | 1637 | 1636 |
| $1.25 billion 5.90 percent thirty year senior notes | USD Fixed | 5.76 | 2054 | 1210 | 1231 |
| $500 million 6.00 percent forty year senior notes | USD Fixed | 5.89 | 2064 | 42 | 492 |
| &nbsp;&nbsp;Total long-term debt |  |  |  | 5137 | 8010 |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: current portion of long-term debt |  |  |  |  | 200 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Long-term debt (excluding current portion) |  |  |  | $5137 | $7810 |

---

***Senior Notes***

The Company's borrowings include $5.0 billion aggregate principal amount of senior notes with maturity dates ranging from 2027 through 2064 (collectively, the "Senior Notes"). The Senior Notes are governed by an indenture and supplemental indenture between the Company and a trustee (collectively, the "Indenture"). The Indenture contains certain customary affirmative and negative covenants, including restrictions on the Company's ability to consolidate, merge, convey, transfer or lease substantially all of its assets. In addition, the Indenture contains other customary terms, including certain events of default, upon the occurrence of which the Senior Notes may be declared immediately due and payable. The Company is in compliance with all covenants related to the Senior Notes.

In September 2025, the Company repurchased multiple series of its outstanding Senior Notes via cash tender offers with a combined aggregate principal amount of $1.9 billion: $650 million aggregate principal amount of 5.45% senior notes due 2027, $797 million aggregate principal amount of 5.40% senior notes due 2029, $22 million aggregate principal amount of 5.90% senior notes due 2054, and $458 million aggregate principal amount of 6.00% senior notes due 2064. Neither the 5.45% senior notes due 2031 nor the 5.60% senior notes due 2034 were tendered.

As a result of tendering a portion of its Senior Notes, the Company recognized a loss on debt extinguishment of approximately $94 million within loss on debt extinguishment, net within its condensed consolidated statements of income, the cash outflow for which is recorded within other financing activities within its condensed consolidated statements of cash flows. This loss on extinguishment reflects the difference between the carrying value and the amount paid to acquire the tendered Senior Notes and related expenses.

***Credit Facilities***

On February 16, 2024, the Company entered into credit agreements providing for:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a five year senior unsecured revolving credit facility in an aggregate committed amount of $2.0 billion expiring in 2029 (the "5-year Revolving Credit Facility"); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• an eighteen month senior unsecured term loan credit facility in an aggregate principal amount of $500 million and a three year senior unsecured term credit loan facility in an aggregate principal amount of $1.0 billion (together, the "Term Loan Credit Facilities," and together with the 5-Year Revolving Credit Facility, the "Credit Facilities"). The Term Loan Credit Facilities have a floating interest rate based on a Secured Overnight Financing Rate ("SOFR") index.

At September 30, 2025, there are no amounts outstanding under the 5-year Revolving Credit Facility.

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

There were no amounts outstanding under the eighteen month senior unsecured term loan facility when it reached maturity in August 2025. In September 2025, the Company prepaid $770 million of the aggregate principal amount outstanding under the three year senior unsecured term loan credit facility.

***Commercial Paper***

On March 4, 2024, the Company entered into a commercial paper program that allows it to issue up to $2.0 billion aggregate principal amount of short-term notes to finance short-term liabilities. Any such issuance will mature within 364 days from date of issue. There was no commercial paper outstanding as of September 30, 2025.

***Future Maturities of Long-term Debt:*** Maturities of long-term debt in the table below reflect the impact of repayment such that total maturities equal the contractual value of long-term debt net of amounts repaid as of September 30, 2025. The maturities of long-term debt for the periods subsequent to September 30, 2025 are as follows (in millions):

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Remainder of<br>2025** | **2026** | **2027** | **2028** | **2029** | **2030** | **After 2030** | **Total** |
| $— | $— | $560 | $— | $703 | $— | $3920 | $5183 |

---

***Financial Instruments Not Measured at Fair Value***

The fair values of cash equivalents, accounts receivable, and accounts payable approximated carrying values because of the short-term nature of these instruments. At September 30, 2025, the estimated fair value of the Company's long-term debt obligations, comprised of both Senior Notes and Term Loan Credit Facilities with current portions excluded, was $5.4 billion compared to a carrying value of $5.1 billion. At December 31, 2024, the estimated fair value of the Company's long-term debt obligations, comprised of both Senior Notes and Term Loan Credit Facilities with current portions excluded, was $7.8 billion compared to a carrying value of $7.8 billion. The fair value was estimated using quoted market prices for the publicly registered Senior Notes, which are classified as Level 2 within the fair value hierarchy. The fair values and principal values consider the terms of the related debt and exclude the impacts of debt discounts. Because there is no active market for trading outstanding term loans, the fair values of the Term Loan Credit Facilities are estimated to be equal to their respective carrying values.

**NOTE 10. Pension and Postretirement Benefit Plans**

***Transfer of Solventum Sponsored Pension and Postretirement Benefit Plans***

Historically, certain employees of Solventum participated in U.S. and non-U.S. retirement plans sponsored by 3M. The primary U.S. defined-benefit pension plan was closed to new participants effective January 1, 2009. In December 2023, 3M committed to the future freeze of U.S. defined benefit pension benefits for non-union U.S. employees, effective December 31, 2028. During March 2024, in advance of the Spin-Off, all U.S. and most remaining 3M sponsored non-U.S. pension and postretirement plan obligations and assets with respect to current and former employees of Solventum were legally transferred to Solventum from 3M, except for certain assets held back within the 3M sponsored pension plans for regulatory purposes. The final asset transfer from the 3M sponsored pension plans occurred in June 2025.

As these plans are sponsored by Solventum, they are accounted for as single employer plans. Therefore, the funded status is reflected in the condensed consolidated balance sheets, and the net periodic benefit costs are included in the condensed consolidated statements of income.

The Company has made deposits for its defined benefit plans with independent trustees. In certain non-U.S. jurisdictions, trust funds and deposits with insurance companies are maintained to provide pension benefits to plan participants and their beneficiaries. There are no plan assets in the U.S. non-qualified plan due to its nature. For the U.S. postretirement health care benefit plan, the Company has set aside amounts at least equal to annual benefit payments with an independent trustee.

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

**C*omponents of net periodic cost and other amounts recognized in other comprehensive (income) loss***

Components of net periodic benefit cost and other supplemental information for the three and nine months ended September 30, 2025 and 2024 are as follows:

**Three months ended September 30,**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Qualified and Non-qualified Pension Benefits** | **Qualified and Non-qualified Pension Benefits** | **Qualified and Non-qualified Pension Benefits** | **Qualified and Non-qualified Pension Benefits** | | |
| | **United States** | **United States** | **International** | **International** | **Postretirement Benefits** | **Postretirement Benefits** |
|<br>**(Millions)** | **2025** | **2024** | **2025** | **2024** | **2025** | **2024** |
| **Net periodic benefit cost (benefit)** |  |  |  |  |  |  |
| &nbsp;&nbsp;Service cost - Operating | $6 | $7 | $5 | $5 | $1 | $1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest cost | 24 | 23 | 5 | 5 | 3 | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Expected return on plan assets | (31) | (34) | (6) | (5) | (2) | (2) |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of prior service benefit |  | (1) |  |  |  | (1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of net actuarial loss | 16 | 14 |  |  | 1 | 1 |
| &nbsp;&nbsp;Non-operating | 9 | 2 | (1) |  | 2 | 1 |
| Total net periodic benefit cost (benefit) | $15 | $9 | $4 | $5 | $3 | $2 |

---

**Nine months ended September 30,**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Qualified and Non-qualified Pension Benefits** | **Qualified and Non-qualified Pension Benefits** | **Qualified and Non-qualified Pension Benefits** | **Qualified and Non-qualified Pension Benefits** | | |
| | **United States** | **United States** | **International** | **International** | **Postretirement Benefits** | **Postretirement Benefits** |
|<br>**(Millions)** | **2025** | **2024** | **2025** | **2024** | **2025** | **2024** |
| **Net periodic benefit cost (benefit)** |  |  |  |  |  |  |
| &nbsp;&nbsp;Service cost - Operating | $18 | $14 | $15 | $14 | $3 | $2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest cost | 72 | 46 | 15 | 15 | 9 | 6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Expected return on plan assets | (93) | (68) | (18) | (15) | (6) | (4) |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of prior service benefit |  | (2) |  |  |  | (2) |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of net actuarial loss | 48 | 28 |  |  | 3 | 2 |
| &nbsp;&nbsp;Non-operating | 27 | 4 | (3) |  | 6 | 2 |
| Total net periodic benefit cost (benefit) | $45 | $18 | $12 | $14 | $9 | $4 |

---

During the nine months ended September 30, 2025, the Company made cash contributions totaling $4 million to its U.S. pension plans and $13 million to its international pension plans. In 2025, the Company expects to make total cash contributions of approximately $23 million to these plans. The Company funds annually, at a minimum, the statutorily required minimum amount for our qualified plans. Non-qualified plans are unfunded and we pay benefits from our cash on hand. Future contributions will depend on market conditions, interest rates and other factors.

On September 1, 2025, in connection with the sale of the Purification and Filtration business, the Company transferred certain eligible U.S. and international employees from Company-sponsored pension and postretirement benefit plans to benefit plans of the Buyer. The transfers required remeasurement of the plans prior to the calculation of the transfer amount. The net impact of the remeasurements was a decrease of approximately $42 million in the pension and postretirement benefits liability and a corresponding decrease in accumulated other comprehensive income (loss). Additionally, the pension and postretirement benefits liability decreased by $33 million related to the curtailment and settlement of benefits for these employees.

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

**NOTE 11. Derivatives**

Prior to April 1, 2024, Solventum indirectly participated in 3M's centrally managed hedging program, which utilizes a number of tools to manage currency risk including natural hedges such as pricing, productivity, hard currency, hard currency-indexed billings, and localizing source of supply. 3M also used financial hedges to mitigate currency risk. After Spin-Off, the Company established its own hedging program.

**Cash Flow Hedges -** For derivative instruments that are designated and qualify as cash flow hedges, the gain or loss on the derivative is reported as a component of other comprehensive income (loss) and reclassified into earnings in the same period during which the hedged transaction affects earnings. Gains and losses on the derivative representing hedge components excluded from the assessment of effectiveness are recognized in current earnings.

***Cash Flow Hedging - Foreign Currency Forward Contracts:*** The Company enters into foreign exchange forward contracts to hedge against the effect of exchange rate fluctuations on cash flows denominated in foreign currencies. These transactions are designated as cash flow hedges. The settlement or extension of these derivatives will result in reclassifications (from accumulated other comprehensive income) to earnings in the period during which the hedged transactions affect earnings. Solventum may de-designate these cash flow hedge relationships in advance of the occurrence of the forecasted transaction. The portion of gains or losses on the derivative instrument previously included in accumulated other comprehensive income (loss) for de-designated hedges remains in accumulated other comprehensive income (loss) until the forecasted transaction occurs or becomes probable of not occurring. Changes in the value of derivative instruments after de-designation are recorded in earnings. The maximum length of time over which Solventum hedges its exposure to the variability in future cash flows of the forecasted transactions is 24 months.

As of September 30, 2025, the Company had a balance of $12 million associated with the after-tax net unrealized loss associated with cash flow hedging instruments recorded in accumulated other comprehensive income. Of the total after-tax net unrealized balance as of September 30, 2025, Solventum expects to reclassify to earnings approximately $8 million after-tax net unrealized loss over the next 12 months based on exchange rates as of September 30, 2025.

The amount of pretax gain (loss) recognized in other comprehensive income (loss) related to derivative instruments designated as cash flow hedges is provided within amount of gain (loss) recognized in AOCI in Note 7.

**Net Investment Hedges -** The Company enters into cross-currency swaps to hedge portions of the Company's investment in foreign subsidiaries and manage foreign exchange risk. For instruments that are designated and qualify as hedges of net investments in foreign operations and that meet the effectiveness requirements, the net gains and losses attributable to changes in spot exchange rates are recorded in cumulative translation within other comprehensive income. The remainder of the change in value of such instruments is recorded in earnings. Recognition in earnings of amounts previously recorded in cumulative translation is limited to circumstances such as complete or substantially complete liquidation of the net investment in the foreign operation.

Solventum's use of cross-currency swaps designated as hedges of the Company's net investment in foreign subsidiaries can vary by time period in connection with the extent of the Company's desired foreign exchange risk coverage.

In March 2025, the Company entered into additional cross-currency swaps designated as net investment hedges of approximately $377 million.

**Derivatives Not Designated as Hedging Instruments -** Derivatives not designated as hedging instruments include foreign currency contracts to offset, in part, the impacts of changes in value of various non-functional currency denominated items including certain intercompany financing balances.

During the third quarter of 2025, the Company entered into $200 million notional fixed-to-floating forward interest rate swaps and $400 million notional treasury locks in connection with the anticipated closing of the Purification and Filtration sale and planned purchase of a portion of our outstanding registered debt. These instruments were settled during the quarter for a gain of $11 million that was reflected within loss on debt extinguishment, net on the condensed consolidated statements of income.

These derivative instruments are not designated in a hedging relationship; therefore, fair value gains and losses on these contracts are recorded in earnings. The Company does not hold or issue derivative financial instruments for trading purposes.

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

***Statement of Income Location and Impact of Derivative Instruments***

The impact to income related to both derivative instruments designated in cash flow hedging relationships and those not designated as hedging instruments for the three and nine months ended September 30, 2025 was not material. The impact from derivative instruments designated in cash flow hedging relationships was reflected within cost of sales and the impact from derivatives not designated as hedging instruments was reflected within other expense (income), net on the condensed consolidated statements of income.&nbsp;&nbsp;&nbsp;&nbsp;

The amount of gain (loss) excluded from effectiveness testing recognized in income relative to instruments designated in net investment hedge relationships is not material.

***Location, Fair Value, and Gross Notional Amounts of Derivative Instruments***

The following tables summarize the fair value of Solventum's derivative instruments and their location in the condensed consolidated balance sheets. Notional amounts below are presented at period end foreign exchange rates.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Gross Notional Amount** | **Gross Notional Amount** | **Assets** | **Assets** | **Assets** | **Liabilities** | **Liabilities** | **Liabilities** |
| **(Millions)** | **Gross Notional Amount** | **Gross Notional Amount** | **Location** | **Fair Value Amount** | **Fair Value Amount** | **Location** | **Fair Value Amount** | **Fair Value Amount** |
| **(Millions)** | **September 30,** | **December 31,** | **Location** | **September 30,** | **December 31,** | **Location** | **September 30,** | **December 31,** |
| **(Millions)** | **2025** | **2024** | **Location** | **2025** | **2024** | **Location** | **2025** | **2024** |
| **Derivatives designated as hedging instruments** | **Derivatives designated as hedging instruments** | **Derivatives designated as hedging instruments** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency forward contracts | $334 | $355 | Other current assets | $2 | $17 | Other current liabilities | $11 | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency forward contracts | 131 | 157 | Other assets |  | 6 | Other liabilities | 4 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cross-currency swaps | 756 | 380 | Other assets |  | $10 | Other liabilities | 64 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total derivatives designated as hedging instruments | $1221 | $892 |  | $2 | $33 |  | $79 | $— |
| **Derivatives not designated as hedging instruments** | **Derivatives not designated as hedging instruments** | **Derivatives not designated as hedging instruments** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency forward contracts | $400 | $397 | Other current assets | $1 | $— | Other current liabilities | $2 | $— |

---

**Fair Value Disclosure:** The Company's derivative assets and liabilities within the scope of ASC 815, *Derivatives and Hedging*, are required to be recorded at fair value. The Company's derivatives that are recorded at fair value include foreign currency forward contracts and cross-currency swaps. Solventum has determined that these derivatives are considered Level 2 fair value measurements. Solventum determines fair value using observable inputs including foreign currency exchange rates.

**Credit Risk and Offsetting of Assets and Liabilities of Derivative Instruments:** The Company is exposed to credit loss in the event of nonperformance by counterparties in forward contracts. However, the Company's risk is limited to the fair value of the instruments. The Company actively monitors its exposure to credit risk through the use of credit approvals and credit limits, and by selecting major international banks and financial institutions as counterparties. Solventum enters into master netting arrangements with counterparties, which may allow each counterparty to net settle amounts owed between a Solventum entity and the counterparty as a result of multiple, separate derivative transactions. The Company does not anticipate nonperformance by any of these counterparties.

Solventum has elected to present the fair value of derivative assets and liabilities within the Company's condensed consolidated balance sheets on a gross basis even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. Solventum determined that the impact of the amount of eligible offsetting derivative assets and liabilities was not material if it had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria in the event of default or termination as stipulated by the terms of netting arrangements with each of the counterparties. For each counterparty, if netted, the Company would offset the asset and liability balances of all derivatives at the end of the reporting period based on the Solventum entity that is a party to the transactions. Derivatives not subject to master netting agreements are not eligible for net presentation. For the periods presented, Solventum has not received cash collateral from derivative counterparties.

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

**NOTE 12. Commitments and Contingencies**

***Legal Proceedings***

Solventum is involved in numerous claims and lawsuits, principally in the United States, and regulatory proceedings worldwide. These claims, lawsuits and proceedings relate to matters including, but not limited to, product liability (involving products that the Company now or formerly manufactured and sold, including products made by the Health Care Business Group at 3M), intellectual property, commercial, antitrust, federal healthcare program related laws and regulations, such as the False Claims Act and anti-kickback laws in the United States and other jurisdictions. Unless otherwise stated, Solventum is vigorously defending all such litigation and proceedings. From time to time, Solventum also receives subpoenas, investigative demands or requests for information from various government agencies in the United States and foreign countries. Solventum generally responds in a cooperative, thorough and timely manner. These responses sometimes require time and effort and can result in considerable costs being incurred by the Company. Such requests can also lead to the assertion of claims or the commencement of administrative, civil, or criminal legal proceedings against Solventum and others, as well as to settlements. The outcomes of legal proceedings and regulatory matters are often difficult to predict. Any determination that the Company's operations or activities are not, or were not, in compliance with applicable laws or regulations could result in the imposition of fines, civil or criminal penalties, and equitable remedies, including disgorgement, suspension or debarment or injunctive relief.

***Process for Disclosure and Recording of Liabilities Related to Legal Proceedings***

Many lawsuits and claims involve highly complex issues relating to causation, scientific evidence, and alleged actual damages, all of which are otherwise subject to substantial uncertainties. Assessments of lawsuits and claims can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions. The categories of legal proceedings in which the Company is involved may include multiple lawsuits and claims, may be spread across multiple jurisdictions and courts that may handle the lawsuits and claims differently, may involve numerous and different types of plaintiffs, raising claims and legal theories based on specific allegations that may not apply to other matters, and may seek substantial compensatory and, in some cases, punitive, damages. These and other factors contribute to the complexity of these lawsuits and claims and make it difficult for the Company to predict outcomes and make reasonable estimates of any resulting losses. The Company's ability to predict outcomes and make reasonable estimates of potential losses is further influenced by the fact that a resolution of one or more matters within a category of legal proceedings may impact the resolution of other matters in that category in terms of timing, amount of liability, or both.

When making determinations about recording liabilities related to legal proceedings, the Company complies with the requirements of ASC 450, *Contingencies*, and related guidance, and records liabilities in those instances where it can reasonably estimate the amount of the loss and when the loss is probable. Where the reasonable estimate of the probable loss is a range, the Company records as an accrual in its financial statements the most likely estimate of the loss, or the low end of the range if there is no one best estimate. The Company either discloses the amount of a possible loss or range of loss in excess of established accruals if estimable, or states that such an estimate cannot be made. The Company discloses significant legal proceedings even where liability is not probable or the amount of the liability is not estimable, or both, if the Company believes there is at least a reasonable possibility that a loss may be incurred. Based on experience and developments, the Company reexamines its estimates of probable liabilities and associated expenses and receivables each period, and whether a loss previously determined to not be reasonably estimable and/or not probable is now able to be reasonably estimated or has become probable. Where appropriate, the Company makes additions to or adjustments of its reasonably estimated losses and/or accruals. As a result, the current accruals and/or estimates of loss and the estimates of the potential impact on the Company's consolidated financial position, results of operations and cash flows for the legal proceedings and claims pending against the Company will likely change over time. During the three and nine months ended September 30, 2025, the Company recognized $0 and $12 million in legal charges, respectively. During both the three and nine months ended September 30, 2024, the Company recognized $3 million and $8 million in legal charges. During the nine months ended September 30, 2025 and 2024 the Company made payments of $16 million and $6 million related to legal settlements. At September 30, 2025 and December 31, 2024, accrued litigation costs were $21 million and $25 million, respectively.

Because litigation is subject to inherent uncertainties, and unfavorable rulings or developments could occur, the Company may ultimately incur charges substantially in excess of presently recorded liabilities, including with respect to matters for which no accruals are currently recorded because losses are not currently probable and reasonably estimable. Many of the matters described herein are at varying stages, seek an indeterminate amount of damages or seek damages in amounts that the Company believes are not indicative of the ultimate losses that may be incurred. It is not uncommon for claims to be resolved over many years. As a matter progresses, the Company may receive information, through plaintiff demands, through discovery, in the form of reports of purported experts, or in the context of settlement or mediation discussions that purport to quantify an amount of alleged damages, but with which the Company may not agree. Such information may or may not lead the Company to determine that it is able to make a reasonable estimate as to a probable loss or range of loss in connection with a matter. However, even when a loss or range of loss is not probable and reasonably estimable, developments in, or the ultimate resolution of, a matter could be material to the Company and could have a material adverse effect on the Company, its

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

consolidated financial position, results of operations and cash flows. In addition, future adverse rulings or developments, or settlements in, one or more matters could result in future changes to determinations of probable and reasonably estimable losses in other matters.

***Process for Disclosure and Recording of Insurance Receivables Related to Legal Proceedings***

The Company estimates insurance receivables based on an analysis of the terms of its numerous policies, including their exclusions, pertinent case law interpreting comparable policies, its experience with similar claims, and assessment of the nature of the claim and remaining coverage, and records an amount it has concluded is recognizable and expects to receive in light of the loss recovery and/or gain contingency models under ASC 450, ASC 610-30, and related guidance. For those insured legal proceedings for which the Company has recorded an accrued liability in its financial statements, the Company also records receivables for the amount of insurance that it concludes as recognizable from the Company's insurance program. For those insured matters for which the Company has not recorded an accrued liability because the liability is not probable or the amount of the liability is not estimable, or both, but for which the Company has incurred an expense in defending itself, the Company records receivables for the amount of insurance that it concludes as recognizable for the expense incurred.

***Product Liability Litigation***

The following sections first describe the significant legal proceedings in which the Company is involved, and then describe the liabilities, if any, the Company has accrued relating to its significant legal proceedings.

3M is a named defendant in over 8,900 lawsuits in the United States and one Canadian putative class action with a single named plaintiff, alleging that they underwent various joint arthroplasty, cardiovascular, and other surgeries and later developed surgical site infections due to the use of the Bair Hugger patient warming system. Under the terms of the Separation and Distribution Agreement by and between Solventum and 3M (the "Separation and Distribution Agreement"), Solventum has agreed to indemnify 3M for uninsured liabilities related to the Bair Hugger patient warming system, to manage the litigation, and pay for legal expenses.

The plaintiffs seek damages and other relief based on theories of strict liability, negligence, breach of express and implied warranties, failure to warn, design and manufacturing defect, fraudulent and/or negligent misrepresentation/concealment, unjust enrichment, and violations of various state consumer fraud, deceptive or unlawful trade practices and/or false advertising acts.

The U.S. Judicial Panel on Multidistrict Litigation ("JPML") has consolidated all cases pending in federal courts to the U.S. District Court for the District of Minnesota to be managed in a multi-district litigation ("MDL") proceeding. In July 2019, the court excluded several of the plaintiffs' causation experts, and granted summary judgment for 3M in all cases pending at that time in the MDL; however, those decisions were subsequently reversed by the U.S. Court of Appeals for the Eighth Circuit. The parties are actively litigating several MDL bellwether and state court cases, with trials anticipated in 2026.

In addition to the federal MDL cases, there are seven state court personal injury cases relating to the Bair Hugger patient warming systems, including a multi-plaintiff case of amputees in Ramsey County, Minnesota. Additionally, a putative class action has been filed in Ramsey County, Minnesota, seeking economic damages for the use of the Bair Hugger system in knee and hip replacement surgeries involving medically obese people in Minnesota from May 2017 to the present.

In June 2016, 3M was served with a putative class action filed in the Ontario Superior Court of Justice for all Canadian residents who underwent various joint arthroplasty, cardiovascular, and other surgeries and later developed surgical site infections that the representative plaintiff claims were due to the use of the Bair Hugger patient warming system. The representative plaintiff seeks relief (including punitive damages) under Canadian law based on theories similar to those asserted in the MDL.

For product liability litigation matters described in this section for which a liability has been recorded, the amount recorded is included in the disclosed amounts in the preceding "*Process for Disclosure and Recording of Liabilities Related to Legal Proceedings*" section and is not material to the Company's results of operations or financial condition. In addition, the Company is not able to estimate a possible loss or range of possible loss in excess of the recorded liability at this time.

***Federal False Claims Act/Qui Tam Litigation***

In October 2019, 3M acquired Acelity, Inc. and its KCI subsidiaries, including Kinetic Concepts, Inc. and KCI USA, Inc. In 2008 two former employees filed qui tam actions against Kinetic Concepts, Inc. and KCI USA, Inc. (collectively, the "KCI Defendants"), alleging that the KCI Defendants violated the federal False Claims Act by submitting false or fraudulent claims to federal healthcare programs related to billing for 3M V.A.C. Therapy. One qui tam action (the Godecke case) was dismissed in January 2022.

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

In the remaining action (the Hartpence case), the litigation remained in a pre-trial stage through July 2023 when the parties agreed to mediate the matter. The parties updated the court periodically during their mediation and subsequent negotiation of an agreement to settle the matter. The parties entered into an agreement resolving the matter on May 15, 2025. On July 2, 2025, pursuant to that agreement, the relator-plaintiff filed a joint stipulation of voluntary dismissal, dismissing the matter with prejudice as to the relator-plaintiff and without prejudice as to the United States. On July 3, 2025, the court entered an order dismissing the matter consistent with the parties' stipulation.

***Warranties/Guarantees***

The Company had approximately $84 million and $40 million in bank guarantees, surety bonds, and other similar instruments issued and outstanding at September 30, 2025 and December 31, 2024, respectively. These instruments are utilized in connection with normal business activities. Furthermore, the Company does not disclose information on its product warranties, as management considers the balance immaterial to its consolidated results of operations and financial condition.

**NOTE 13. Restructuring**

In the fourth quarter of 2024, the Company announced its Solventum Way restructuring program, which is a reorganization designed to establish a more flexible and decentralized structure, create headroom to invest for growth and an operating model that enhances margins over time. Solventum expects that substantially all actions under this program will be complete by the end of 2025.

The related restructuring charges for periods presented were recorded in the condensed consolidated statement of income as follows:

---

| | | |
|:---|:---|:---|
| | **Three months ended September 30,** | **Nine months ended September 30,** |
|<br>**(Millions)** | **2025** | **2025** |
| Cost of product | $(2) | $9 |
| Cost of software and rentals |  |  |
| Selling, general and administrative expenses | 4 | 14 |
| Research and development expenses |  | 5 |
| &nbsp;&nbsp;Total operating income impact | $2 | $28 |

---

Restructuring actions, including cash and non-cash impacts, are as follows:

---

| | | | |
|:---|:---|:---|:---|
| **(Millions)** | **Employee Termination Benefits** | **Asset-Related and Other** | **Total** |
| Expense incurred in 2024 | $46 | $16 | $62 |
| Non-cash changes |  | (8) | (8) |
| Cash payments | (1) |  | (1) |
| Accrued liabilities as of December 31, 2024 | $45 | $8 | $53 |
| Expense incurred in first quarter of 2025 | $14 | $4 | $18 |
| Non-cash changes |  | (4) | (4) |
| Cash payments | (38) |  | (38) |
| Accrued liabilities as of March 31, 2025 | $21 | $8 | $29 |
| Expense incurred in second quarter of 2025 | $9 | $(1) | $8 |
| Cash payments | (9) | (2) | (11) |
| Accrued liabilities as of June 30, 2025 | $21 | $5 | $26 |
| Expense incurred in third quarter of 2025 | $5 | $(3) | $2 |
| Cash payments | (14) |  | (14) |
| Accrued liabilities as of September 30, 2025 | $13 | $1 | $14 |

---

Asset-related and other primarily includes charges associated with asset write-offs and other contractual third party termination costs. All program charges were recognized within Corporate and are not included within business segment results.

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

**NOTE 14. Earnings Per Share**

Prior to the completion of the Spin-Off, the Company had no common shares issued and outstanding. On April 1, 2024, there were 172,709,505 shares of Solventum common stock issued and outstanding as part of the Distribution. For the nine months ended September 30, 2024, these shares are treated as issued and outstanding for purposes of calculating historical earnings per share.

Subsequent to Spin-Off, the dilutive effect of outstanding stock options, restricted stock units ("RSUs") and performance share units ("PSUs") is reflected in the calculation of earnings per share using the treasury stock method. Diluted earnings per share excludes certain shares issuable under stock-based compensation plans because the effect would have been antidilutive.

The computations for basic and diluted earnings per share are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
|<br>**(Amounts in millions, except per share amounts)** | **2025** | **2024** | **2025** | **2024** |
| Numerator: |  |  |  |  |
| &nbsp;&nbsp;Net income | $1266 | $122 | $1493 | $448 |
| Denominator: |  |  |  |  |
| &nbsp;&nbsp;Weighted average common shares outstanding – basic  | 174.3 | 173.4 | 174.0 | 173.1 |
| &nbsp;&nbsp;Dilution associated with stock-based compensation plans | 1.1 | 0.5 | 1.1 | 0.3 |
| &nbsp;&nbsp;Weighted average common shares outstanding – diluted | 175.4 | 173.9 | 175.1 | 173.4 |
| Basic earnings per share | $7.26 | $0.70 | $8.58 | $2.59 |
| Diluted earnings per share | $7.22 | $0.70 | $8.53 | $2.58 |
| Antidilutive shares | 4.3 | 5.0 | 4.1 | 5.0 |

---

**NOTE 15. Stock-Based Compensation**

Solventum grants annual stock-based compensation awards to certain employees and non-employee directors. In 2025, the Company's annual grant occurred in the first quarter and included: 1.2 million RSUs that vest over 3 years with a weighted average grant date fair value of $75.74 and 0.4 million PSUs that vest based on a combination of service, performance and market conditions, with a weighted average grant date fair value of $83.15. The actual number of PSUs that vest could range from 0% to 200% of the target number of shares granted, and will be determined based on the Company's performance against financial targets and total shareholder return relative to a selected industry peer group; performance is measured over a three-year period ending December 31, 2027.

The annual grant contains a retirement provision whereby employees who have reached age 55 and completed ten years of service with the Company will continue to vest in their award after they retire. For these awards, expense is recognized over the required service period. The compensation cost of awards to grant recipients who meet these conditions on the grant date is recognized on the grant date.

**Stock-Based Compensation Expense**

Amounts recognized in the condensed consolidated financial statements related to stock-based compensation awards, including stock options, RSUs, and PSUs, are provided in the following table. Total stock-based compensation expense recognized in cost of product and cost of software and rentals has been combined in the table below within Cost of sales. Capitalized stock-based compensation amounts were not material.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
|<br>**(Millions)** | **2025** | **2024** | **2025** | **2024** |
| Cost of sales | $2 | $3 | $10 | $12 |
| Selling, general and administrative expenses | 36 | 22 | 100 | 61 |
| Research and development expenses | 3 | 2 | 14 | 14 |
| Stock-based compensation expenses | 41 | 27 | 124 | 87 |
| Income tax benefits (expense) | (6) | (5) | (17) | (13) |
| Stock-based compensation expenses, net of tax | $35 | $22 | $107 | $74 |

---

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

**NOTE 16. Related Parties**

**Related Party Transactions Prior to Spin-Off**

Prior to the Spin-Off, the Company participated in centralized 3M treasury programs. This arrangement was not reflective of the manner in which the Company would have financed its operations had it been a standalone business separate from 3M during the periods presented prior to April 1, 2024. All adjustments relating to certain transactions among the Company and 3M, which include the transfer of the balance of cash to and from 3M, transfer of the balance of cash held in centralized cash management arrangements to and from 3M, and pushdown of all costs of doing business that were paid on behalf of the Company by 3M, are excluded from the asset and liability balances in the condensed consolidated balance sheets and have instead been reported within Net parent investment as a component of equity*.*

***Corporate Allocations***

The condensed consolidated statements of income for periods prior to April 1, 2024 include general corporate expenses of 3M for services provided by 3M for certain corporate and shared service functions that were provided on a centralized basis, including the use of shared assets. Expenses had been included on a direct usage basis where costs were specifically identifiable to Solventum or allocated based on the Company's pro rata proportion of 3M's revenue.

Management believes that the expense allocations were determined on a basis that was a reasonable reflection of the utilization of services provided for or the benefit received by the Company during each of the periods presented prior to April 1, 2024. The amounts that would have been incurred on a standalone basis could materially differ from the amounts allocated. Management does not believe, however, that it is practicable to estimate what these expenses would have been had the Company operated as an independent entity, including any expenses associated with obtaining any of these services from unaffiliated entities. There was no expense allocation activity from 3M after April 1, 2024.

3M expense allocations were recorded in the condensed consolidated statements of income within the following captions:

---

| | | |
|:---|:---|:---|
| | **Three months ended September 30,** | **Nine months ended September 30,** |
|<br>**(Millions)** | **2024** | **2024** |
| Cost of product | $— | $15 |
| Cost of software and rentals |  |  |
| Selling, general and administrative expenses |  | 177 |
| Research and development expenses |  | 28 |
| Total | $— | $220 |

---

**Related Party Transactions After Spin-Off**

***Separation and Distribution Agreement and Other Related Party Transactions with 3M***

In connection with the Spin-Off on April 1, 2024, the Company entered into or adopted several agreements that provide a framework for Solventum's relationship with 3M after the separation and distribution. Below is a summary of activity between Solventum and 3M for the periods presented:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* Separation related adjustments, which are the net impact of certain assets and liabilities that were retained by 3M and those that were transferred to Solventum as of March 31, 2024&nbsp;&nbsp;&nbsp;&nbsp;, resulted in a decrease to net assets and total equity of $1.1 billion in the second quarter of 2024. This activity was reflected in the "Net transfers to 3M" line item of the condensed consolidated statements of changes in equity. The impact on net assets primarily represents liabilities payable to 3M for services received prior to Spin-Off as well as cash and accounts receivable retained by 3M.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Transition agreement expenses for the three and nine months ended September 30, 2025 were $145 million and $417 million, respectively, and for both the three and nine months ended September 30, 2024 were $144 million and $231 million, respectively, and are related to services received under transition agreements between the Company and 3M and its affiliates. These expenses are reflected in cost of product and operating expense (which is comprised of selling, general and administrative and research and development expenses) on the Company's condensed consolidated statements of income.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Master Supply Agreements - The Company recognized revenue and cost of sales associated with products sold to 3M of $22 million and $17 million, respectively, for the three months ended September 30, 2025 and $64 million and $48 million, respectively, for the nine months ended September 30, 2025. The Company recognized revenue and cost of

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

sales associated with products sold to 3M of $17 million and $12 million, respectively, for the three months ended September 30, 2024 and $27 million and $20 million, respectively, for the nine months ended September 30, 2024. Cost of product related to purchases from 3M under the master supply agreements was $64 million and $185 million for the three and nine months ended September 30, 2025, respectively. Cost of product related to purchases from 3M under the master supply agreements was $68 million for the three and nine months ended September 30, 2024.

***Related Party Transactions***

The Company had the following transactions with 3M and its affiliates, primarily in connection with the transition and master supply agreements, reported in the Company's condensed consolidated financial statements:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
|<br>**(Amounts in millions)** | **2025** | **2024** | **2025** | **2024** |
| Net sales of product | $22 | $17 | $64 | $27 |
| Cost of product | 167 | 171 | 481 | 201 |
| Selling, general and administrative expenses | 67 | 63 | 193 | 135 |
| Research and development expenses | 2 | 2 | 8 | 5 |

---

Current amounts due from and due to 3M under various agreements described above are recognized within the due from related parties and due to related parties, as applicable, in the condensed consolidated financial statements. There were no non-current amounts due to 3M at September 30, 2025.

**Net Parent Investment**

Net transfers to 3M are included within Net parent investment in the condensed consolidated statements of changes in equity and within financing activities in the condensed consolidated statements of cash flows and represent the net effect of transactions between the Company and 3M.

The reconciliation of net transfers to 3M between the condensed consolidated changes in equity and the condensed consolidated statements of cash flows are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
|<br>**(Millions)** | **2025** | **2024** | **2025** | **2024** |
| Net transfers from (to) 3M on the condensed consolidated changes in equity | $9 | $— | $(21) | $(8575) |
| Stock compensation expense |  |  |  | (4) |
| Multiemployer pension expense |  |  |  | (5) |
| Net balances transferred from 3M |  |  |  | 337 |
| Net transfers from (to) 3M on the condensed consolidated statements of cash flows | $9 | $— | $(21) | $(8247) |

---

**NOTE 17. Business Segments**

Operating segments include components of an enterprise where separate financial information is available that is evaluated regularly by the Company's Chief Operating Decision Maker ("CODM") for the purpose of assessing performance and allocating resources. The Company's CODM is its Chief Executive Officer. The primary profitability measurement used by the CODM to review segment operating results is segment operating income. The CODM uses segment operating income to allocate resources during the strategic planning process and then holds the segments accountable to the resourcing decisions during the annual budgeting process. The CODM does not use asset information by segment to evaluate reportable segments as the CODM does not receive discrete asset information by segment. Beginning in third quarter 2025, as a result of the sale of the Purification and Filtration business, the Company's operating activities are managed primarily through the following reportable segments: MedSurg, Dental Solutions, and Health Information Systems. There have been no changes to the composition of or to financial information reported within each of these reportable segments. These segments have been identified based on the nature of the products sold and how the Company manages its operations. Transactions among reportable segments are recorded at cost. No operating segments have been aggregated to form reportable segments.

All Other includes the Water Business, which was previously reported within the Purification and Filtration business segment. The Water Business results have been reclassified for comparability within All Other for all historical periods. All Other also includes sales and cost of sales related to our supply agreements with 3M and other supply agreements assumed by the Company at Spin-Off related to legacy 3M businesses, which were historically included in Corporate and Unallocated.

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

Corporate and Unallocated primarily includes restructuring and related charges, benefits or costs related to capitalized manufacturing variances, and Spin-Off and separation related costs. Spin-Off and separation related costs include any costs incurred as part of our separation from 3M and costs to set up operations as a standalone company, including system implementations, manufacturing relocation, legal entity separation, certain equity awards granted as part of the Spin-Off, profit mark-ups on transition service arrangements with 3M and other one-time costs.

Because Corporate and Unallocated includes a variety of miscellaneous items, it is subject to fluctuation on a quarterly and annual basis. Business segment operating income is reconciled to total operating income and pre-tax income below.

Consistent accounting policies have been applied on a consolidated basis as well as by all segments for all reporting periods.

**Business Segment Information and Disaggregated Net Sales**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
|<br>**Net Sales (Millions)** | **2025** | **2024** | **2025** | **2024** |
| &nbsp;&nbsp;Advanced Wound Care | $485 | $468 | $1400 | $1369 |
| &nbsp;&nbsp;Infection Prevention and Surgical Solutions | 722 | 713 | 2182 | 2093 |
| MedSurg | 1206 | 1182 | 3581 | 3463 |
| Dental Solutions | 340 | 313 | 1006 | 979 |
| Health Information Systems | 345 | 326 | 1012 | 971 |
| &nbsp;&nbsp;**Total reportable segment net sales** | 1891 | 1821 | 5600 | 5413 |
| Purification and Filtration | 128 | 180 | 497 | 532 |
| All Other | 77 | 81 | 230 | 234 |
| &nbsp;&nbsp;**Total net sales** | $2096 | $2082 | $6327 | $6179 |
|  | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
| **Cost of Sales (Millions)** | **2025** | **2024** | **2025** | **2024** |
| MedSurg | $599 | $539 | $1750 | $1593 |
| Dental Solutions | 118 | 109 | 350 | 320 |
| Health Information Systems | 80 | 92 | 259 | 269 |
|  | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
| **Operating Expenses (Millions)\*** | **2025** | **2024** | **2025** | **2024** |
| MedSurg | $405 | $399 | $1213 | $1192 |
| Dental Solutions | 134 | 130 | 394 | 382 |
| Health Information Systems | 131 | 129 | 391 | 385 |
| \* Operating expenses are comprised of selling, general and administrative expenses and research and development expenses as shown on the condensed consolidated statements of income. | \* Operating expenses are comprised of selling, general and administrative expenses and research and development expenses as shown on the condensed consolidated statements of income. | \* Operating expenses are comprised of selling, general and administrative expenses and research and development expenses as shown on the condensed consolidated statements of income. | \* Operating expenses are comprised of selling, general and administrative expenses and research and development expenses as shown on the condensed consolidated statements of income. | \* Operating expenses are comprised of selling, general and administrative expenses and research and development expenses as shown on the condensed consolidated statements of income. |
|  | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
| **Operating Performance (Millions)** | **2025** | **2024** | **2025** | **2024** |
| MedSurg | $203 | $243 | $619 | $678 |
| Dental Solutions | 87 | 74 | 262 | 277 |
| Health Information Systems | 134 | 105 | 363 | 317 |
| &nbsp;&nbsp;**Total reportable segment operating income** | 424 | 422 | 1244 | 1272 |
| Purification and Filtration | 26 | 19 | 96 | 62 |
| All Other | 12 | 5 | 31 | 24 |
| Amortization expense | (77) | (88) | (235) | (261) |
| Corporate and Unallocated | 1305 | (83) | 921 | (197) |
| &nbsp;&nbsp;**Total operating income** | 1690 | 275 | 2057 | 900 |
| Interest expense, net | 89 | 107 | 296 | 260 |
| Loss on extinguishment of debt, net | 82 |  | 82 |  |
| Other expense/(income), net | 5 | 1 | 24 | 48 |
| &nbsp;&nbsp;**Income before income taxes** | $1514 | $167 | $1655 | $592 |

---

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

**NOTE 18. Subsequent Events**

***Transform for the Future***

In November 2025, the Company approved its new multiyear 'Transform for the Future' global initiative (the "Program") to further enable its long-term growth strategy and ensure it's best positioned to compete-to-win in a rapidly changing healthcare environment. Designed to transform the cost structure, enhance operational efficiency, and reposition for profitable growth, the primary activities of the Program include operating structure optimization and workforce reorganization, procurement and cost management, supply chain, manufacturing and global footprint optimization, and streamlining systems and increased automation to improve operational efficiency. Once fully implemented, the 4-year Program is expected to generate approximately $500 million in annual cost savings, a portion of which will be reinvested in strategic growth initiatives. The Company anticipates cumulative pretax costs related to the Program will be approximately $500 million.

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the Company's condensed consolidated financial statements and corresponding notes elsewhere in this Quarterly Report on Form 10-Q. The following discussion and analysis provides information management believes to be relevant to understanding the financial condition and results of operations of Solventum for the nine months ended September 30, 2025 and 2024. For full understanding of the Company's financial condition and results of operations, the below discussion should be read alongside the Management's Discussion and Analysis of Financial Condition and Results of Operations included in the Company's 2024 Annual Report on Form 10-K. This discussion contains forward-looking statements that are based upon current expectations and are subject to uncertainty and changes in circumstances. Our actual results could differ materially from the results contemplated by these forward-looking statements due to a number of factors, including those discussed below and elsewhere in this Quarterly Report on Form 10-Q, and particularly in Item 1A, "Risk Factors" in the Company's 2024 Annual Report on Form 10-K.

All amounts discussed are in millions of U.S. dollars, unless otherwise indicated. Amounts reported within this interim report are rounded to the nearest million and the sum of the components may not equal the total amount reported due to rounding. Additionally, certain columns and rows within tables may not sum due to rounding.

Unless the context otherwise requires, references to "Solventum" and the "Company" refer to (i) 3M's Health Care Business prior to the Spin-Off as a carve-out business of 3M and (ii) Solventum Corporation and its subsidiaries following the Spin-Off.

***Transition to Standalone Company***

Solventum utilized allocations and carve-out methodologies through the date of the Spin-Off to prepare combined financial statements. The condensed consolidated financial statements herein for periods prior to the Spin-Off may not be indicative of the Company's future performance, do not necessarily include the actual expenses that would have been incurred, and may not reflect our results of operations, financial position, and cash flows had we been a separate, standalone company during the historical periods presented.

Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is designed to provide a reader of Solventum's financial statements with a narrative from the perspective of management. Solventum's MD&A is presented in the following sections:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Overview

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Results of Operations

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Performance by Business Segment

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Financial Condition and Liquidity

**Overview**

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

***Operating Segments and Sales Change Information***

Solventum manages its operations in three business segments: MedSurg, Dental Solutions, and Health Information Systems. On February 25, 2025, the Company entered into a Transaction Agreement to sell its Purification and Filtration business to Buyer. On June 25, 2025, the Company and Buyer entered into an additional Agreement to exclude the Company's Water Business from the scope of the Business to be acquired by Buyer. On September 1, 2025, Solventum completed the sale of the Business to the Buyer in accordance with the terms of the Agreement. The cash consideration paid to Solventum at closing was approximately $4 billion. Refer to Note 3, "Acquisitions and Divestitures" for additional information.

References are made to organic sales change, which is defined as the change in net sales, absent the separate impacts on sales from foreign currency translation and acquisitions, net of divestitures. Constant currency, as reflected in the tables below, is defined as the change in net sales absent the impact on sales from foreign currency translation. Other, as comprised in the tables below, includes acquisition and divestiture-related activities. Acquisitions include non-health care related supply agreements that conveyed from 3M to the Company at Spin-Off and sales from new supply agreements with 3M that commenced at Spin-Off. Divestiture impacts include lost sales from both the Company's Purification and Filtration business that was sold in September 2025 and the dental anesthetics business that was sold in August 2023, as well as lost sales from certain health care businesses retained by 3M India in connection with the Spin-Off. Solventum believes this information is useful to investors and management in understanding ongoing operations and in analysis of ongoing operating trends.

***Sales and operating income by business segment:***

The following tables contain sales and operating results by business segment for all periods presented. The Company's use of the term "NM" reflects results considered not material due to either not having material activity in comparable prior years or is not meaningful. Refer to the section entitled "—Performance by Business Segment" below for discussion of sales change and operating performance. Refer to Note 17 to the condensed consolidated financial statements for additional information on business segments.

***Segment and Total Company Net Sales***

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Increase/(Decrease)** | **Increase/(Decrease)** | **Increase/(Decrease)** | **Increase/(Decrease)** | **Increase/(Decrease)** |
|<br>**(Millions)** | **2025** | **2024** | **Reported Growth** | **Currency Impact** | **Constant Currency** | **Other** | **Organic Growth** |
| **Segment Sales** |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Advanced Wound Care | $485 | $468 | 3.5% | 0.8% | 2.7% | —% | 2.7% |
| &nbsp;&nbsp;Infection Prevention and Surgical Solutions | 722 | 713 | 1.2 | 1.1 | 0.1 |  |  |
| MedSurg | 1206 | 1182 | 2.1 | 1.0 | 1.1 |  | 1.1 |
| Dental Solutions | 340 | 313 | 8.4 | 1.9 | 6.5 |  | 6.5 |
| Health Information Systems | 345 | 326 | 5.9 | 0.3 | 5.6 |  | 5.6 |
| Purification and Filtration | 128 | 180 | (28.7) | 3.4 | (32.1) | (38.5) | 6.4 |
| All Other | 77 | 81 | (5.4) | 0.4 | (5.8) |  | (5.8) |
| Total Company | $2096 | $2082 | 0.7% | 1.1% | (0.4)% | (3.1) % | 2.7% |
|  | **Nine months ended September 30,** | **Nine months ended September 30,** | **Increase/(Decrease)** | **Increase/(Decrease)** | **Increase/(Decrease)** | **Increase/(Decrease)** | **Increase/(Decrease)** |
| **(Dollars in millions)** | **2025** | **2024** | **Reported Growth** | **Currency Impact** | **Constant Currency** | **Other** | **Organic Growth** |
| **Segment Sales** |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Advanced Wound Care | $1400 | $1369 | 2.2% | 0.2% | 2.0% | (0.1)% | 2.1% |
| &nbsp;&nbsp;Infection Prevention and Surgical Solutions | 2182 | 2093 | 4.2 | 0.1 | 4.1 | (0.5) | 4.6 |
| MedSurg | 3581 | 3463 | 3.4 | 0.1 | 3.3 | (0.3) | 3.6 |
| Dental Solutions | 1006 | 979 | 2.8 | 0.5 | 2.3 | (0.3) | 2.5 |
| Health Information Systems | 1012 | 971 | 4.3 | 0.1 | 4.2 |  | 4.2 |
| Purification and Filtration | 497 | 532 | (6.6) | 1.0 | (7.6) | (13.1) | 5.5 |
| All Other | 230 | 234 | (2.0) | 0.1 | (2.1) | 5.6 | (7.6) |
| Total Company | $6327 | $6179 | 2.4% | 0.2% | 2.2% | (1.1) % | 3.2% |

---

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

***Segment and Total Company Operating Income***

---

| | | | |
|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Three months ended September 30,** |
|<br>**(Millions)** | **2025** | **2024** | **2025 vs 2024 change** |
| **Segment Operating Income** |  |  |  |
| MedSurg | $203 | $243 | (16.5)% |
| Dental Solutions | 87 | 74 | 18.7 |
| Health Information Systems | 134 | 105 | 27.4 |
| Purification and Filtration | 26 | 19 | 36.8 |
| All Other | 12 | 5 | 140.0 |
| Corporate and Unallocated | 1228 | (171) | 818.1 |
| Total Company | $1690 | $275 | 514.5% |
|  | **Nine months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
| **(Dollars in millions)** | **2025** | **2024** | **2025 vs 2024 change** |
| **Segment Operating Income** |  |  |  |
| MedSurg | $619 | $678 | (8.7)% |
| Dental Solutions | 262 | 277 | (5.4) |
| Health Information Systems | 363 | 317 | 14.5 |
| Purification and Filtration | 96 | 62 | 54.8 |
| All Other | 31 | 24 | 29.2 |
| Corporate and Unallocated | 686 | (458) | 249.8 |
| Total Company | $2057 | $900 | 128.6% |

---

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

***Net Sales by Geographic Area***

While the Company manages its businesses globally and believes its business segment results are the most relevant measure of performance, the Company also utilizes geographic area data as a secondary performance measure. Sales are generally reported within the geographic area based on the location of the customer taking possession of the products or in which services are rendered.

Percent change information compares the three and nine months ended September 30, 2025 with the same period for the prior year, unless otherwise indicated.

---

| | | | |
|:---|:---|:---|:---|
| | **Three months ended September 30, 2025** | **Three months ended September 30, 2025** | **Three months ended September 30, 2025** |
|<br>**(Millions)** | **United States** | **International** | **Worldwide** |
| Net sales | $1184 | $912 | $2096 |
| &nbsp;&nbsp;&nbsp;&nbsp;% of worldwide sales | 56.5% | 43.5% | 100.0% |
| &nbsp;&nbsp;Increase/(decrease) |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Organic growth | 3.4% | 1.7% | 2.7% |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | (1.5) | (5.2) | (3.1) |
| &nbsp;&nbsp;Constant currency | 1.9 | (3.5) | (0.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;Currency impact |  | 2.6 | 1.1 |
| Reported growth | 1.9% | (0.9)% | 0.7% |
|  | **Nine months ended September 30, 2025** | **Nine months ended September 30, 2025** | **Nine months ended September 30, 2025** |
| **(Millions)** | **United States** | **International** | **Worldwide** |
| Net sales (millions) | $3513 | $2814 | $6327 |
| &nbsp;&nbsp;&nbsp;&nbsp;% of worldwide sales | 55.5% | 44.5% | 100.0% |
| &nbsp;&nbsp;Increase/(decrease) |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Organic growth | 3.6% | 2.7% | 3.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | (0.2) | (2.1) | (1.1) |
| &nbsp;&nbsp;Constant currency | 3.4 | 0.6 | 2.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Currency impact |  | 0.5 | 0.2 |
| Reported growth | 3.4% | 1.1% | 2.4% |

---

Additional information beyond what is included in the preceding table is as follows:

***Third quarter 2025 results:***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In the United States geographic area, both total sales and organic sales increased. Organic growth occurred across all segments, led by MedSurg and Health Information Systems.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In the International geographic area, total sales decreased while organic sales increased. Organic growth was led by Dental Solutions.

***First nine months 2025 results:***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In the United States geographic area, both total sales and organic sales increased. Organic growth occurred across all segments, led by MedSurg and Health Information Systems.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In the International geographic area, both total sales and organic sales increased. Organic growth was led by MedSurg, partially offset by a decline in Purification and Filtration.

***Managing currency risks***

Prior to April 1, 2024, Solventum indirectly participated in 3M's centrally managed hedging program. Starting in the second quarter of 2024, Solventum established its own hedging program. Refer to Note 11 to the condensed consolidated financial statements for additional details.

Foreign currency had a positive worldwide impact on sales for the third quarter 2025 compared to the same period last year. The worldwide impact on sales for the nine months ended 2025 was positive compared to the same period last year. Solventum estimates that year-on-year foreign currency transaction effects, including hedging impacts, decreased pre-tax income by

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

approximately $4 million and increased pre-tax income by approximately $6 million for the three and nine months ended September 30, 2025, respectively.

***Financial condition***

Refer to the section entitled "—Financial Condition and Liquidity" below for a discussion of items impacting cash flows.

**Results of Operations**

***Net Sales***

Refer to the preceding "—Overview" section and the "—Performance by Business Segment" section later in MD&A for discussion of sales change.

***Operating Expenses***

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
|<br>**(Percent of corresponding net sales)** | **2025** | **2024** | **Change** | **2025** | **2024** | **Change** |
| Cost of product | 53.1% | 49.3% | 3.8% | 52.4% | 49.1% | 3.3% |
| Cost of software and rentals | 22.7 | 26.2 | (3.5) | 24.3 | 25.8 | (1.5) |

---

***Cost of Product***

Cost of product includes manufacturing, engineering and freight costs.

Cost of product, measured as a percent of sales of product, increased in the third quarter of 2025 when compared to the third quarter of 2024. The increase was driven by increased costs due to the impact of higher sourcing costs from tariffs and inventory sourced under the master supply and transition manufacturing agreements with 3M, partially offset by benefits from cost savings programs.

Cost of product, measured as a percent of sales of product, increased in the first nine months of 2025 when compared to the first nine months of 2024. The increase was driven by increased costs due to the impact of higher sourcing costs from tariffs and inventory sourced under the master supply and transition manufacturing agreements with 3M partially offset by benefits from cost savings programs.

***Cost of Software and Rentals***

Cost of software and rentals includes compensation-related costs associated with installation, training and maintenance for our software products, and depreciation, maintenance and refurbishment cost and freight costs related to our hardware rental units.

Cost of software and rentals, measured as a percent of sales of software and rentals, decreased during the third quarter of 2025 as compared to the same period last year due to the impact, primarily driven by benefits from lower external license fees and product mix benefit from higher sales of our revenue cycle management solutions.

Cost of software and rentals, measured as a percent of sales of software and rentals, decreased during the first nine months of 2025 as compared to the same period last year due to the impact of lower external license fees, price and sales mix, primarily driven by higher sales of our revenue cycle management solution.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
|<br>**(Percent of total net sales)** | **2025** | **2024** | **Change** | **2025** | **2024** | **Change** |
| Selling, general and administrative (SG&A) | 37.2% | 33.7% | 3.5% | 36.7% | 32.3% | 4.4% |
| Research and development (R&D) | 8.7 | 9.1 | (0.4) | 8.9 | 9.3 | (0.4) |
| Gain on sale of business | (72.4) |  | (72.4) | (24.0) |  | (24.0) |
| Operating income | 80.6 | 13.2 | 67.4 | 32.5 | 14.6 | 17.9 |

---

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

***Selling, General and Administrative***

SG&A, measured as a percent of total net sales, increased in the third quarter of 2025 when compared to the same period last year. The increase was driven by higher costs associated with activities to separate operations from 3M, costs incurred to separate the Purification and Filtration business, and higher compensation expense, including equity-based awards, partially offset by benefits from the Solventum Way restructuring program.

SG&A, measured as a percent of total net sales, increased in the first nine months of 2025 when compared to the same period last year. The increase was driven by costs incurred to separate the Purification and Filtration business, higher compensation, including equity-based awards, and higher costs associated with both initial stand-up and ongoing operations to support a standalone company.

***Research and Development***

R&D, measured as a percent of total net sales, decreased in the third quarter of 2025 when compared to the same period last year due to lower cost from the sale of the Purification and Filtration business in relation to higher net sales.

R&D, measured as a percent of total net sales, decreased in the first nine months of 2025 when compared to the same period last year due to lower cost from the sale of the Purification and Filtration business in relation to higher net sales.

***Gain on Sale of Business***

The Company completed the sale of the Purification and Filtration business in the third quarter of 2025. This resulted in a net gain of $1.5 billion for both the third quarter and first nine months of 2025.

***Interest Expense, Net, Loss on Debt Extinguishment, Net, and Other Expense (Income), Net***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
|<br>**(Millions)** | **2025** | **2024** | **2025** | **2024** |
| Interest expense, net | $89 | $107 | $296 | $260 |
| Loss on debt extinguishment, net | 82 |  | 82 |  |
| Other expense (income), net | 5 | 1 | $24 | $48 |

---

Interest expense, net includes interest accrued on debt obligations, offset by interest income from cash and marketable securities. Interest expense, net decreased in the third quarter as compared to the same period last year due to lower interest expense as a result of lower debt outstanding. Interest expense, net increased in the first nine months of 2025 as compared to the same period last year due to a full quarter of interest incurred in the first quarter of 2025 related to the February 2024 issuance of senior notes and March 2024 draw on the senior term loan credit facilities. Refer to Note 9 to the condensed consolidated financial statements for more information.

Loss on debt extinguishment, net includes charges incurred in the third quarter of 2025 from the differential between carrying value and the amount paid to acquire the tendered Senior Notes and related expenses. Refer to Note 9 to the condensed consolidated financial statements for additional information. These charges were partially offset by the gain from interest rate swaps entered into and subsequently settled in connection with the sale of the Purification and Filtration business. Refer to Note 11 to the condensed consolidated financial statements for additional information.

Other expense (income), net includes the non-service component of periodic pension cost, investment gains and losses, and foreign currency transaction gain (loss). Other expense (income), net increased for the third quarter of 2025 primarily due to higher non-service periodic pension costs. Other expense (income), net decreased for the nine months of 2025 as compared to the same period last year primarily due to charges associated with the substantial liquidation of foreign operations completed as part of our separation from 3M.

***Provision for (benefit from) Income Taxes:***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
|<br>**(Percent of pre-tax income/loss)** | **2025** | **2024** | **2025** | **2024** |
| Effective tax rate | 16.4% | 26.9% | 9.8% | 24.3% |

---

Refer to Note 8 to the condensed consolidated financial statements for further discussion of income taxes.

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

**Performance by Business Segment**

Note 17 to the condensed consolidated financial statements provides an overview of Solventum's business segments in addition to disclosures relating to Solventum's segments. Upon closing the sale of our Purification and Filtration business, we primarily manage our operations in three business segments. Our reportable segments are MedSurg, Dental Solutions, and Health Information Systems. Our Chief Operating Decision Maker evaluates segment operating performance using net sales and business segment operating income.

***All Other***

All Other primarily consists of the Water Business that was retained after the sale of the Purification and Filtration Business. All Other also includes sales and cost of sales related to our agreements to supply 3M and other supply agreements assumed by the Company at Spin-Off related to legacy 3M businesses, which were historically included within Corporate and Unallocated.

***Corporate and Unallocated***

Certain items are maintained at the corporate level and not allocated to the segments ("Corporate and Unallocated"). Corporate and Unallocated includes amortization of acquired intangible assets, restructuring and related charges, and benefits or costs related to capitalized manufacturing variances. In addition, Corporate and Unallocated includes Spin-Off and separation related costs. Spin-Off and separation related costs include any costs incurred as part of our separation from 3M and costs to setup operations as a standalone company, including system implementations, manufacturing relocations, legal entity separations, certain equity awards granted as part of the Spin-Off, profit mark-ups on transition service arrangements with 3M and other one-time costs.

Because Corporate and Unallocated includes a variety of miscellaneous items, it is subject to fluctuation on a quarterly and annual basis.

***Business Segment Information***

Information related to the Company's segments is presented in the tables that follow with additional context in the corresponding narrative below the tables.

***MedSurg (*57.5% *and 56.6% of consolidated sales for the three and nine months ended September 30, 2025)***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
|<br>**(Millions)** | **2025** | **2024** | **2025** | **2024** |
| Net sales | $1206 | $1182 | $3581 | $3463 |
| &nbsp;&nbsp;&nbsp;Increase/(decrease) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Organic growth | 1.1% | 1.0% | 3.6% | 1.1% |
| &nbsp;&nbsp;&nbsp;&nbsp;Other |  | (0.7) | (0.3) | (0.5) |
| &nbsp;&nbsp;&nbsp;Constant currency | 1.1 | 0.2 | 3.3 | 0.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Currency impact | 1.0 | (0.1) | 0.1 | (0.6) |
| Reported growth | 2.1% | 0.1% | 3.4% | —% |
| Business segment operating income | $203 | $243 | $619 | $678 |
| &nbsp;&nbsp;&nbsp;&nbsp;Percent change | (16.5)% | (20.8)% | (8.7)% | (18.2)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Percent of sales | 16.8% | 20.6% | 17.3% | 19.6% |

---

***Third quarter 2025 results:***

Sales in MedSurg were up 2.1%:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Organic growth was driven by volumes in Advanced Wound Care, due to negative pressure wound therapy. Growth within our Infection Prevention and Surgical Solutions business was negatively impacted by advanced order timing as part of enterprise resource planning and distribution center cutovers that occurred during the second quarter 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Foreign currency translation positively impacted sales by 1.0%.

Business segment operating income margin decreased when compared to the same period last year. The decrease was primarily driven by the impact of higher product costs due to tariffs.

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

***First nine months 2025 results:***

Sales in MedSurg were up 3.4%:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Organic growth was led by Infection Prevention and Surgical Solutions, led by I.V. site management and surgical solutions products.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Other includes certain health care businesses retained by 3M India in connection with the Spin-Off.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Foreign currency translation positively impacted sales by 0.1%.

Business segment operating income margin decreased when compared to the same period last year. The decrease was driven by higher costs to stand-up and operate our standalone structure after Spin-Off and the impact on product cost from tariffs.

***Dental Solutions (*16.2% *and 15.9% of consolidated sales for the three and nine months ended September 30, 2025)***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
|<br>**(Millions)** | **2025** | **2024** | **2025** | **2024** |
| Net sales | $340 | $313 | $1006 | $979 |
| &nbsp;&nbsp;&nbsp;Increase/(decrease) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Organic growth | 6.5% | (3.9)% | 2.5% | (1.8)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Other |  | (1.2) | (0.3) | (1.9) |
| &nbsp;&nbsp;&nbsp;Constant currency | 6.5 | (5.2) | 2.3 | (3.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;Currency impact | 1.9 |  | 0.5 | (0.6) |
| Reported growth | 8.4% | (5.2)% | 2.8% | (4.3)% |
| Business segment operating income | $87 | $74 | $262 | $277 |
| &nbsp;&nbsp;&nbsp;Percent change | 18.7% | (35.1)% | (5.4)% | (20.6)% |
| &nbsp;&nbsp;&nbsp;Percent of sales | 25.7% | 23.6% | 26.1% | 28.3% |

---

***Third quarter 2025 results:***

Sales in Dental Solutions were up 8.4%:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Organic growth across all businesses, led by new restorative and prevention solutions products. The quarter benefitted from a reduction in backorders driven by improved service levels.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Foreign currency translation positively impacted sales by 1.9%.

Business segment operating income margin increased when compared to the same period last year primarily due to the benefit of higher sales volume growth. Tariff and inflation impacts were largely offset by savings from Solventum Way and other supply chain benefits.

***First nine months 2025 results:***

Sales in Dental Solutions were up 2.8%:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Organic growth in new restorative and prevention solutions products was partially offset by a decline in traditional orthodontic products.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Other includes certain health care businesses retained by 3M India in connection with the Spin-Off.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Foreign currency translation positively impacted sales by 0.5%

Business segment operating income margin decreased when compared to the same period last year as a result of higher costs to stand-up and operate our standalone structure after Spin-Off.

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

***Health Information Systems (*16.5% *and 16.0% of consolidated sales for the three and nine months ended September 30, 2025)***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
|<br>**(Millions)** | **2025** | **2024** | **2025** | **2024** |
| Net sales | $345 | $326 | $1012 | $971 |
| &nbsp;&nbsp;&nbsp;Increase/(decrease) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Organic growth | 5.6% | 1.5% | 4.2% | 1.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;Other |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Constant currency | 5.6 | 1.4 | 4.2 | 1.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Currency impact | 0.3 | 0.1 | 0.1 |  |
| Reported growth | 5.9% | 1.5% | 4.3% | 1.8% |
| Business segment operating income | $134 | $105 | $363 | $317 |
| &nbsp;&nbsp;&nbsp;Percent change | 27.4% | (7.9)% | 14.5% | 4.3% |
| &nbsp;&nbsp;&nbsp;Percent of sales | 38.8% | 32.2% | 35.8% | 32.6% |

---

***Third quarter 2025 results:***

Sales in Health Information Systems were up 5.9%:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Organic growth was driven by continued adoption of our Solventum™ 360 Encompass<sup>TM</sup> and a timing benefit from consulting product milestones.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Clinician productivity solutions declined primarily due to impacts from changing market conditions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Foreign currency translation positively impacted sales by 0.3%.

Business segment operating income margin increased when compared to the same period last year, driven by sales mix and lower external license fees.

***First nine months 2025 results:***

Sales in Health Information Systems were up 4.3%:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Positive organic growth was driven by continued adoption of our Solventum™ 360 Encompass<sup>TM</sup> and performance management solutions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Clinician productivity solutions declined primarily due to impacts from changing market conditions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Foreign currency translation positively impacted sales by 0.1%.

Business segment operating income margin increased when compared to the same period last year, driven by sales price growth, product mix and lower external license fees.

***Other Segment Information***

***Purification and Filtration***

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended September 30,** | **Three months ended September 30,** | **Nine months ended September 30,** | **Nine months ended September 30,** |
|<br>**(Millions)** | **2025** | **2024** | **2025** | **2024** |
| Net sales | $128 | $180 | $497 | $532 |
| &nbsp;&nbsp;&nbsp;Increase/(decrease) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Organic growth | 6.4% | 4.1% | 5.5% | 5.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | (38.5) | (1.3) | (13.1) | (1.0) |
| &nbsp;&nbsp;&nbsp;Constant currency | (32.1) | 2.8 | (7.6) | 4.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Currency impact | 3.4 |  | 1.0 | (0.6) |
| Reported growth | (28.7)% | 2.8% | (6.6)% | 3.6% |
| Business segment operating income | $26 | $19 | $96 | $62 |
| &nbsp;&nbsp;&nbsp;Percent change | 36.8% | (31.3)% | 54.8% | (11.6)% |
| &nbsp;&nbsp;&nbsp;Percent of sales | 20.1% | 10.6% | 19.3% | 11.7% |

---

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

***Third quarter 2025 results:***

Sales in Purification and Filtration were down (28.7)%:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Results above represent the two months of sales prior to the close of the sale in September 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Other includes lost sales from the Company's Purification and Filtration business that was sold in September 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Foreign currency translation positively impacted sales by 3.4%.

Business segment operating income margin increased due to volume growth and favorable sales mix.

***First nine months 2025 results:***

Sales in Purification and Filtration were down (6.6)%:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Organic growth was driven by growth in both bioprocessing filtration and industrial filtration, which benefited from added production capacity, partially offset by declines in membrane OEM products.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Other includes lost sales from the Company's Purification and Filtration business that was sold in September 2025 and certain health care businesses retained by 3M India in connection with the Spin-Off.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Foreign currency translation positively impacted sales by 1.0%.

Business segment operating income margin increased due to volume growth, favorable sales mix and a benefit resulting from the Company stopping depreciation on assets classified as held for sale, partially offset by additional standalone structure costs.

**Financial Condition and Liquidity**

The strength and stability of Solventum's operating model and strong free cash flow capability provides financial flexibility and enables the Company to invest through business cycles. Historically, Solventum generated positive operating cash flows and a majority of such cash flows were transferred to 3M as part of 3M's cash pooling arrangements, the effect of which is presented as Net transfers to 3M in our consolidated financial statements.

***Debt and Credit Facilities***

Refer to Note 9 of the Company's condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for information on the Company's long-term debt and short-term borrowings.

The Company had approximately $84 million and $40 million in bank guarantees, surety bonds, and other similar instruments issued and outstanding at September 30, 2025 and December 31, 2024, respectively. These instruments are utilized in connection with normal business activities.

***Commercial Paper***

On March 4, 2024, the Company entered into a commercial paper program that allows it to issue up to $2.0 billion aggregate principal amount of short-term notes to finance short-term liabilities. Any such issuance will mature within 364 days from date of issue. There was no commercial paper outstanding as of September 30, 2025.

***Cash, cash equivalents and marketable securities***

As of September 30, 2025, Solventum had $1,642 million of cash and cash equivalents, of which approximately $1,438 million was held by the Company's foreign subsidiaries and approximately $204 million was held in the United States. These balances are invested in bank instruments and other high-quality fixed income securities. As of December 31, 2024, Solventum had $762 million of cash and cash equivalents, of which approximately $611 million was held by the Company's foreign subsidiaries and $151 million was held in the United States. There were immaterial amounts of marketable securities at both September 30, 2025 and December 31, 2024. The increase from December 31, 2024 was driven by proceeds from the sale of the Purification and Filtration business, partially offset by repurchases of a portion of our senior notes via tender offers and a prepayment on our outstanding term loan.

***Cash Flows***

Cash flows from operating, investing and financing activities are provided in the tables that follow. Individual amounts in the condensed consolidated statements of cash flows exclude the effect of exchange rate impacts on cash and cash equivalents, which are presented separately in the cash flows. Thus, the amounts presented in the following operating, investing and financing activities tables reflect changes in balances from period to period adjusted for these effects.

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

---

| | | |
|:---|:---|:---|
| | **Nine months ended September 30,** | **Nine months ended September 30,** |
|<br>**(Millions)** | **2025** | **2024** |
| **Cash provided by (used in):** |  |  |
| &nbsp;&nbsp;Operating activities | $274 | $966 |
| &nbsp;&nbsp;Investing activities | 3542 | (253) |
| &nbsp;&nbsp;Financing activities | (2942) | (136) |
| Effect of exchange rate changes on cash and cash equivalents | 6 | 1 |
| Net increase (decrease) in cash and cash equivalents | $880 | $578 |

---

***Operating Activities***

In the first nine months of 2025, cash flows provided by operating activities decreased compared to the first nine months of 2024 primarily due to lower net income, excluding the gain on sale of the Purification and Filtration business, transaction costs on sale of the business, higher inventories, and accrued compensation activity.

***Investing Activities***

The increase in investing activities is related to proceeds from sale of the Purification and Filtration business in September 2025.

Purchases of property, plant and equipment increased in the first nine months of 2025 as compared to the first nine months of 2024. The increase is primarily driven by additional separation related capital spending as the Company relocates manufacturing and source of supply from 3M. In addition, the Company is focused on investments to support growth, renewal and maintenance programs, and environmental health services.

***Financing Activities***

For the first nine months of 2025, cash flows used by financing activities increased as compared to the first nine months of 2024, primarily due to the Company's repayment of $1.9 billion of senior notes via tender offers upon completion of the sale of the Purification and Filtration business and $770 million repayment of outstanding principal issued under the senior term loan credit facility.

***Material Cash Requirements from Known Contractual and Other Obligations:***

Solventum's material cash requirements from known contractual and other obligations primarily relate to the following, for which information on both a short-term and long-term basis is provided in the indicated notes to the condensed consolidated financial statements:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Tax obligations—Refer to Note 8 to the condensed consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Debt—Refer to Note 9 to the condensed consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Commitments and contingencies—Refer to Note 12 to the condensed consolidated financial statements.

Solventum purchases the majority of its materials and services as needed, with no unconditional commitments. In limited circumstances, in the normal course of business, the Company enters into unconditional purchase obligations with various vendors that may take the form of, for example, take or pay contracts in which the Company guarantees payment to ensure availability of certain materials or services or to ensure ongoing efforts on capital projects. The Company expects to receive underlying materials or services for these purchase obligations. To the extent these purchase obligations fluctuate, it largely trends with normal-course changes in regular operating activities. Additionally, contractual capital commitments represent a small part of the Company's expected capital spending.

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

**Cautionary Note Concerning Forward Looking Statements** 

This Quarterly Report on Form 10-Q, including "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Part I, Item 2, and other materials Solventum has filed or will file with the SEC (and oral communications that Solventum may make) contain or incorporate by reference statements that relate to future events and expectations and, as such, constitute forward-looking statements that involve risk and uncertainties. Forward-looking statements include those containing such words as "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "guidance," "intends," "may," "outlook," "plans," "projects," "seeks," "sees," "should," "targets," "will," "would," or other words of similar meaning.

All statements that reflect Solventum's expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, forecasts relating to discussions of future operations and financial performance (including volume growth, pricing, sales and earnings per share growth and cash flows) and statements regarding Solventum's strategy for growth, future product development, regulatory clearances and approvals, competitive position and expenditures. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and changes in circumstances that are difficult to predict. Although Solventum believes that the expectations reflected in any forward-looking statements it makes are based on reasonable assumptions, it can give no assurance that these expectations will be attained and it is possible that actual results may differ materially from those indicated by these forward-looking statements due to a variety of risks and uncertainties. Such risks and uncertainties include, but are not limited to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the effects of, and changes in, worldwide economic, political, regulatory, international, trade and geopolitical conditions, natural disasters, war, public health crises, and other events beyond Solventum's control;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• operational execution risks;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• damage to our reputation or our brands;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• risks from acquisitions, strategic alliances, divestitures and other strategic events, including the divestiture of our Purification and Filtration business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Solventum's business dealings involving third-party partners in various markets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Solventum's ability to access the capital and credit markets and changes in Solventum's credit ratings;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• exposure to interest rate and currency risks;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the highly competitive environment in which Solventum operates and consolidation in the healthcare industry;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• reduction in customers' research budgets or government funding;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the timing and market acceptance of Solventum's new product and service offerings;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• ongoing working relationships with certain key healthcare professionals;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• changes in reimbursement practices of governments or private payers or other cost containment measures;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Solventum's ability to obtain components or raw materials supplied by third parties and other manufacturing and related supply chain difficulties, interruptions, and disruptive factors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• legal and regulatory proceedings and legal compliance risks (including third-party risks) with regards to antitrust, Foreign Corrupt Practices Act ("FCPA") and other anti-bribery laws, environmental laws, anti-kickback and false claims laws, privacy laws, tax laws, and other laws and regulations in the United States and other countries in which Solventum operates;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• potential liabilities related to a broad group of perfluoroalkyl and polyfluoroalkyl substances, collectively known as "PFAS";

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• risks related to the highly regulated environment in which Solventum operates;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• risks associated with product liability claims;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• climate change and measures to address climate change;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• security breaches and other disruptions to information technology infrastructure;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Solventum's failure to obtain, maintain, protect, or effectively enforce its intellectual property ("IP") rights;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• pension and postretirement obligation liabilities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• any failure by 3M to perform any of its obligations under the various separation agreements in connection with the Spin-Off;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• any failure to realize the expected benefits of the Spin-Off;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a determination by the IRS or other tax authorities that the Spin-Off or certain related transactions should be treated as taxable transactions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• financing transactions undertaken in connection with the Spin-Off and risks associated with additional indebtedness;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the risk that incremental costs of operating on a standalone basis (including the loss of synergies), costs of restructuring transactions and other costs incurred in connection with the Spin-Off will exceed Solventum's estimates; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the impact of the Spin-Off on its businesses and the risk that the Spin-Off may be more difficult, time-consuming or costly than expected, including the impact on its resources, systems, procedures and controls, diversion of

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

management's attention and the impact on relationships with customers, suppliers, employees and other business counterparties.

The above list is not exhaustive or necessarily set forth in the order of importance. Forward-looking statements are based on certain assumptions and expectations of future events and trends, and actual future results and trends may differ materially from historical results or those reflected in any such forward-looking statements depending on a variety of factors. Solventum assumes no obligation to update or revise such statement, whether as a result of new information, future events or otherwise, except as required by applicable law.

Important information as to these factors can be found in this document, including, among others, "Management's Discussion and Analysis of Financial Condition and Results of Operations" under the headings of "Overview," "Financial Condition and Liquidity" and annually in "Critical Accounting Estimates." Discussion of these factors is incorporated by reference from Part II, Item 1A, "Risk Factors," of this document, and should be considered an integral part of Part I, Item 2, "Management's Discussion and Analysis of Financial Condition and Results of Operations." For additional information concerning factors that may cause actual results to vary materially from those stated in the forward-looking statements, see our reports on Form 8-K filed with the SEC from time to time and the Company's Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC. Any forward-looking statement speaks only as of the date on which it is made, and Solventum assumes no obligation to update or revise such statement, whether as a result of new information, future events or otherwise, except as required by applicable law.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

***Foreign Currency Exchange Rate Risks:***

Solventum faces transactional exchange rate risk from transactions with customers in countries outside the United States and from intercompany transactions between affiliated entities. Foreign currency exchange rates and fluctuations in those rates may cause fluctuations in cash flows related to foreign denominated transactions. The Company is also exposed to the translation of foreign currency earnings to the U.S. dollar.

***Commodity Prices Risk:***

Solventum manages commodity price risks through negotiated supply contracts and price protection agreements. The Company does not participate in material commodity hedging activity.

**Item 4. Controls and Procedures**

*Evaluation of Disclosure Controls and Processes*

The Company carried out an evaluation, under the supervision and with the participation of its management, including the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company's "disclosure controls and procedures" (as defined in the Exchange Act Rule 13a-15(e)) as of the end of the period covered by this report. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures are effective.

*Changes in Internal Controls Over Financial Reporting*

During the quarter ended June 30, 2025, we completed the initial phase of a new SAP enterprise resource planning system implementation, which we expect will enhance our transactional processing and financial reporting. The implementation included changes to certain financial processes impacting key controls related to our internal controls over financial reporting. We believe we have maintained appropriate internal control over financial reporting during the implementation and will continue to monitor the impact of the implementation on our processes, procedures and internal control over financial reporting. There have been no other changes in the Company's internal control over financial reporting (as such term is defined in Rule 13a-15(f) of the Exchange Act) that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

**SOLVENTUM CORPORATION**

**FORM 10-Q**

**For the Quarterly Period Ended September 30, 2025**

**PART II. Other Information**

**Item 1. Legal Proceedings**

Discussion of legal matters is incorporated by reference from Part I, Item 1, Note 12, "Commitments and Contingencies," of this document, and should be considered an integral part of Part II, Item 1, "Legal Proceedings."

**Item 1A. Risk Factors**

There have been no material changes to the risk factors as disclosed in our 2024 Annual Report on Form 10-K.

Discussion of these factors is incorporated by reference into and considered an integral part of Part I, Item 2, "Management's Discussion and Analysis of Financial Condition and Results of Operations."

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

There were no unregistered sales of equity securities during the period covered by this report.

**Item 3. Defaults Upon Senior Securities**

No matters require disclosure.

**Item 4. Mine Safety Disclosures**

Not applicable.

**Item 5. Other Information**

*Insider Trading Arrangements and Policies*

During the three months ended September 30, 2025, no director or officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.

*Availability of Information*

Solventum's website address is www.solventum.com. Investors and others should note that the Company announces material information to its investors using SEC filings, press releases, its investor relations website, public conference calls, webcasts and certain social media channels, including the following LinkedIn accounts: https://www.linkedin.com/in/bryanchanson/, and https://www.linkedin.com/in/wayde-mcmillan-9b233b33/. The Company uses these channels to communicate with investors, customers and the public about the Company, its products and other issues and for complying with its disclosure obligations under Regulation FD. The information on, or that may be accessed through, Solventum's website is not incorporated by reference into this Quarterly Report on Form 10-Q and should not be considered a part of this Quarterly Report on Form 10-Q.

------

<u>[**Table of Contents**](#ia4603513ea7a402eb8e3e09303999c25_10)</u> 

**Item 6. Exhibits**

---

| | |
|:---|:---|
| (3.1) | <u>[Amended and Restated Certificate of Incorporation of Solventum Corporation (incorporated by reference to Exhibit 3.1 from Solventum's Form 8-K, filed April 4, 2024)](https://www.sec.gov/Archives/edgar/data/1964738/000162828024014887/exhibit31-8xk.htm)</u> |
| (3.2) | <u>[Amended and Restated Bylaws of Solventum Corporation (incorporated by reference to Exhibit 3.1 from Solventum's Form 8-K, filed September 26, 2024)](https://www.sec.gov/Archives/edgar/data/1964738/000196473824000027/solventumbylaws92024.htm)</u> |
| (4.1) | <u>[Indenture, dated as of February 27, 2024, between Solventum Corporation and U.S. Bank Trust Company, N.A., as successor trustee, with respect to Solventum's senior notes, is incorporated by reference from Exhibit 4.1 to Amendment No.2 to the Company's Registration Statement on Form 10, filed March 11, 2024.](https://www.sec.gov/Archives/edgar/data/1964738/000162828024009297/exhibit41-form10x12ba.htm)</u> |
| (4.2) | <u>[First Supplemental Indenture, dated as of February 27, 2024, to Indenture dated as of February 27, 2024, between Solventum Corporation and U.S. Bank Trust Company, N.A., as successor trustee, with respect to Solventum's senior debt notes, is incorporated by reference from Exhibit 4.2 to Amendment No. 2 to the Company's Registration Statement on Form 10, filed March 11, 2024.](https://www.sec.gov/Archives/edgar/data/1964738/000162828024009297/exhibit42-form10x12ba.htm)</u> |

---

Filed herewith, in addition to items, if any, specifically identified above:

---

| | |
|:---|:---|
| (31.1) | <u>[Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350.](a2025q310-qexhibit311.htm)</u> |
| (31.2) | <u>[Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350.](a2025q310-qexhibit312.htm)</u> |
| (32.1) | <u>[Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350.](a2025q310-qexhibit321.htm)</u> |
| (32.2) | <u>[Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350.](a2025q310-qexhibit322.htm)</u> |
| (101.INS) | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) |
| (101.SCH) | Inline XBRL Taxonomy Extension Schema Document |
| (101.CAL) | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| (101.DEF) | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| (101.LAB) | Inline XBRL Taxonomy Extension Label Linkbase Document |
| (101.PRE) | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| (104) | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SOLVENTUM CORPORATION

(Registrant)

---

| | | |
|:---|:---|:---|
| Date: November 6, 2025 | | |
| | By | /s/ Wayde McMillan |
| | | &nbsp;&nbsp;&nbsp;Wayde McMillan, |
| | Executive Vice President and Chief Financial Officer (Mr. McMillan is a Principal Financial Officer and has been duly authorized to sign on behalf of the Registrant.) | Executive Vice President and Chief Financial Officer (Mr. McMillan is a Principal Financial Officer and has been duly authorized to sign on behalf of the Registrant.) |

---

## Exhibit 31.1

**EXHIBIT 31.1**

**CERTIFICATION PURSUANT TO**

**SECTION 302**

**OF THE SARBANES-OXLEY ACT OF 2002**

I, Bryan Hanson, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this Quarterly Report on Form 10-Q of Solventum Corporation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| November 6, 2025 | /s/ Bryan Hanson |
| | Bryan Hanson |
| | Chief Executive Officer |
| | (Principal Executive Officer) |

---

## Exhibit 31.2

**EXHIBIT 31.2**

**CERTIFICATION PURSUANT TO**

**SECTION 302**

**OF THE SARBANES-OXLEY ACT OF 2002**

I, Wayde McMillan, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this Quarterly Report on Form 10-Q of Solventum Corporation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| November 6, 2025 | /s/ Wayde McMillan |
| | Wayde McMillan |
| | Chief Financial Officer |
| | (Principal Financial Officer) |

---

## Exhibit 32.1

**EXHIBIT 32.1**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350**

**AS ADOPTED PURSUANT TO SECTION 906**

**OF THE SARBANES-OXLEY ACT OF 2002**

I, Bryan Hanson, Chief Executive Officer of Solventum Corporation (the "Company"), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.

---

| | |
|:---|:---|
| November 6, 2025 | /s/ Bryan Hanson |
| | Bryan Hanson |
| | Chief Executive Officer |
| | (Principal Financial Officer) |

---

## Exhibit 32.2

**EXHIBIT 32.2**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350**

**AS ADOPTED PURSUANT TO SECTION 906**

**OF THE SARBANES-OXLEY ACT OF 2002**

I, Wayde McMillan, Chief Financial Officer of Solventum Corporation (the "Company"), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.

---

| | |
|:---|:---|
| November 6, 2025 | /s/ Wayde McMillan |
| | Wayde McMillan |
| | Chief Financial Officer |
| | (Principal Financial Officer) |

---

<br>